结直肠癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT05482516 / NCI-2023-01487

Evaluating Response to Atezolizumab and Bevacizumab Treatment in Patients with Gastrointestinal Cancers and Minimal Residual Disease using ctDNA

AI 简述这是一项3期试验，评估Atezolizumab联合贝伐珠单抗用于ctDNA阳性胃肠癌，包括结肠、直肠、胃癌等，在美国开展。

?

适用疾病: Metastatic Gastric Adenocarcinoma；Metastatic Hepatocellular Carcinoma；Locally Advanced Pancreatic Adenocarcinoma
干预: 未列出
地点: United States
申办方: MedStar Georgetown University Hospital

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06362395 / NCI-2025-05948

Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

AI 简述这是一项III期试验，研究超高剂量立体定向放疗用于肝转移，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Toronto Western Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT02885753

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

AI 简述这是一项III期试验，在比利时和法国等地开展，比较静脉奥沙利铂与肝动脉化疗联合LV5FU2+/-伊立替康及靶向治疗用于肝转移结直肠癌。

?

适用疾病: Colorectal Neoplasms
干预: Oxaliplatin intravenous，5 FU bolus，Folinic acid，Oxaliplatin intra-arteriel
地点: Belgium，France
申办方: Federation Francophone de Cancerologie Digestive

正在招募 Phase 3 药物其他

ClinicalTrials.gov / NCI NCT03803553 / NCI-2020-01521

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

AI 简述这是一项III期试验，研究治疗手段用于III期结肠癌的微转移灶。在美国开展。

?

适用疾病: Metastatic Colon Cancer；Stage III Colon Cancer；Colon Adenocarcinoma
干预: FOLFIRI Protocol，ACTIVE SURVEILLANCE，Nivolumab Protocol，Encorafenib/Binimetinib/Cetuximab Protocol
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 3 药物

ClinicalTrials.gov NCT04776655

Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

AI 简述这是一项III期试验，比较FOLFIRI联合西妥昔单抗或贝伐珠单抗用于RAS/BRAF野生型组织且RAS突变液态活检阳性的转移性结直肠癌，在意大利开展。

?

适用疾病: Colorectal Cancer；Metastatic Colorectal Cancer；RAS Mutation
干预: Bevacizumab，Cetuximab，5-FU，Irinotecan
地点: Italy
申办方: Azienda USL Reggio Emilia - IRCCS

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05008809

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

AI 简述这是一项III期试验，比较术后辅助化疗方案用于转移性结直肠癌。

?

适用疾病: Colorectal Cancer
干预: mFOLFOX6，mFOLFOXIRI，FOLFIRI，CAPOX
地点: Germany
申办方: Dominik Paul Modest

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT05673148 / NCI-2022-09253

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

AI 简述这是一项III期试验，在有限转移性结直肠癌中，评估在常规全身治疗基础上增加立体定向消融放疗、手术或微波消融。在美国和加拿大开展。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Stage IV Colorectal Cancer AJCC v8；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Stereotactic Ablative Radiotherapy，Resection，Microwave Ablation，Chemotherapy
地点: United States，Canada
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05770102

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

AI 简述这是一项2/3期试验，研究Atezolizumab用于高肿瘤突变负荷、MSI-high或CMMRD的肿瘤，在英国开展。

?

适用疾病: Malignancy；Malignant Neoplasm；Lymphoproliferative Disorders
干预: Atezolizumab
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05786716

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

AI 简述这是一项II/III期试验，研究Trastuzumab联合Pertuzumab用于HER2扩增或激活突变的成人和儿童癌症。在英国开展。

?

适用疾病: Haematological Malignancy；Colorectal Neoplasms；Urinary Bladder Neoplasm
干预: Trastuzumab，Pertuzumab
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT05861505

COLLISION RELAPSE Trial

AI 简述这是一项III期试验，比较新辅助系统治疗与重复局部治疗用于结直肠癌肝转移，在荷兰开展。

?

适用疾病: Colorectal Cancer；Liver Metastases；Liver Metastasis Colon Cancer
干预: Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)，Repeat local treatment
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募 Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05863195 / NCI-2023-02357

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

AI 简述这是一项III期试验，比较泵化疗联合标准治疗与单独标准治疗用于不可切除的结直肠癌肝转移。

?

适用疾病: Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm in the Liver；Stage IV Colorectal Cancer AJCC v8
干预: Bevacizumab，Cetuximab，Computed Tomography，Floxuridine
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06134388

Sulfasalazine in Patients With Metastatic Colorectal Cancer

AI 简述这是一项III期试验，研究Sulfasalazine用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Sulfasalazine
地点: Egypt
申办方: Tanta University

正在招募 Phase 2, Phase 3 手术/操作放疗

ClinicalTrials.gov NCT06185556

COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases

AI 简述这是一项II/III期试验，在荷兰开展，比较不可逆电穿孔与立体定向体部放疗用于血管周围和胆管周围结直肠癌肝转移。

?

适用疾病: Colorectal Cancer；Liver Metastases；Liver Metastasis Colon Cancer
干预: Irreversible electroporation，Stereotactic body radiotherapy
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06226857

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

AI 简述这是一项III期试验，研究西妥昔单抗用于左侧RAS野生型转移性结直肠癌。在俄罗斯开展。

?

适用疾病: Colorectal Neoplasms；Chemotherapy Effect；Molecular Sequence Variation
干预: Cetuximab
地点: Russia
申办方: City Clinical Oncology Hospital No 1

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06243393

Sacituzumab Govitecan in Metastatic Colorectal Cancer

AI 简述这是一项II/III期试验，比较Sacituzumab Govitecan与医生选择用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Sacituzumab Govitecan (SG)，Physicians Choice (PhC).
地点: Germany
申办方: University Hospital Heidelberg

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06252649 / NCI-2024-03471

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

AI 简述这是一项III期试验，比较Sotorasib、Panitumumab、FOLFIRI与FOLFIRI联合或不联合Bevacizumab-awwb用于KRAS G12C突变转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma
干预: FOLFIRI Regimen，Sotorasib，Panitumumab，Bevacizumab-awwb
地点: United States，Argentina，Australia，Austria 等 31 个
申办方: Amgen

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06275958

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

AI 简述这是一项III期试验，比较不同剂量化疗用于老年转移性结直肠癌，在荷兰开展。

?

适用疾病: Older Patients；Colorectal Cancer；Metastatic Cancer
干预: Doublet Chemotherapy, Standard Dose (100%)，Doublet Chemotherapy, Dose-reduced (75%)，Monotherapy, Standard Dose (100%)，Monotherapy, Dose-reduced (75%)
地点: Netherlands
申办方: Leiden University Medical Center

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06509126

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

AI 简述这是一项III期试验，研究间歇或持续帕尼单抗联合化疗用于左侧RAS/B-RAF野生型转移性结直肠癌。

?

适用疾病: Colorectal Cancer Stage IV
干预: Panitumumab，Irinotecan，5-fluorouracil，L-folinic acid
地点: Italy
申办方: National Cancer Institute, Naples

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06555003

DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases

AI 简述这是一项III期试验，在伊朗开展，研究DEBIRI联合化疗对比单独化疗用于结直肠癌肝转移。

?

适用疾病: Liver Neoplasm；Colorectal Cancer Metastatic
干预: Drug-Eluting Embolic Bead，Chemotherapy drug
地点: Iran
申办方: Tehran University of Medical Sciences

正在招募 Phase 3 其他手术/操作

ClinicalTrials.gov / NCI NCT06563388 / NCI-2024-06801

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

AI 简述这是一项III期试验，研究立体定向消融放疗用于寡转移癌症患者，包括肺癌、结直肠癌和前列腺癌。

?

适用疾病: Oligometastasis；Lung Cancer；Colo-rectal Cancer
干预: Stereotactic Ablative Radiotherapy，Best Practice
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06642844

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

AI 简述这是一项III期试验，在法国开展，研究贝伐珠单抗适应性化疗用于不可切除转移性结直肠癌。

?

适用疾病: Unresectable Metastatic Colorectal Cancer
干预: Avastin, 25 Mg/mL Intravenous Solution
地点: France
申办方: University Hospital, Tours

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06733038

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

AI 简述这是一项III期试验，比较FOLFOXIRI加贝伐珠单抗联合或不联合Atezolizumab一线治疗pMMR且IC-High转移性结直肠癌。在意大利开展。

?

适用疾病: Colorectal Cancer
干预: Atezolizumab，Bevacizumab，Irinotecan (CPT-11)，Oxaliplatin
地点: Italy
申办方: Gruppo Oncologico del Nord-Ovest

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07228832 / NCI-2025-09154

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

AI 简述这是一项III期试验，比较Ivonescimab联合FOLFOX与贝伐珠单抗联合FOLFOX用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: Drug: Ivonescimab Injection，Drug: Bevacizumab Injection
地点: United States，Belgium，Canada，Czechia 等 8 个
申办方: Summit Therapeutics

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07284849 / NCI-2026-01397

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

AI 简述这是一项III期试验，研究化疗和贝伐珠单抗联合或不联合INCA33890用于转移性结直肠癌。

?

适用疾病: CRC (Colorectal Cancer)；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: INCA33890，Placebo，Bevacizumab，FOLFOX
地点: United States，Argentina，Australia，Austria 等 17 个
申办方: Incyte Corporation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07389265

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

AI 简述这是一项III期试验，评估一线后继续使用西妥昔单抗联合化疗用于转移性结直肠癌，在意大利、西班牙开展。

?

适用疾病: Metastatic Colorectal Cancer (mCRC)
干预: Erbitux (Cetuximab)，Bevacizumab，FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)，FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
地点: Italy，Spain
申办方: University of Campania Luigi Vanvitelli

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07525206 / NCI-2026-03965

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

AI 简述这是一项III期试验，比较Telisotuzumab adizutecan联合贝伐珠单抗与标准治疗用于转移性结直肠癌。

?

适用疾病: Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Colorectal Cancer
干预: Telisotuzumab adizutecan，Bevacizumab，Trifluridine/Tipiracil
地点: United States，Belgium，Japan，Portugal 等 2 个
申办方: AbbVie

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07549412

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

AI 简述这是一项3期试验，研究Precemtabart tocentecan联合或不联合贝伐珠单抗用于转移性结直肠癌，在美国和澳大利亚开展。

?

适用疾病: Metastatic Colorectal Cancer
干预: Precemtabart tocentecan，Bevacizumab，Trifluridine/Tipiracil (FTD-TPI)
地点: United States，Australia
申办方: EMD Serono Research & Development Institute, Inc.

正在招募 Phase 1, Phase 2

NCI NCT03018405 / NCI-2017-00722

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

AI 简述这是一项I/II期试验，研究多种肿瘤适应症的药物。

?

适用疾病: Metastatic Urothelial Cancer；Advanced Malignant Solid Tumor；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Celyad Oncology SA

正在招募 Phase 2

NCI NCT03259867 / NCI-2017-01862

Combination of TATE and PD-1 Inhibitor in Liver Cancer

AI 简述这是一项II期试验，研究Nivolumab联合肝动脉栓塞用于肝癌和胃癌。

?

适用疾病: BCLC Stage C Hepatocellular Cancer；Metastatic Gastric Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Teclison Ltd.

正在招募 Phase 1, Phase 2

NCI NCT03190941 / NCI-2018-03522

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

AI 简述这是一项I/II期试验，研究输注靶向KRAS G12V的T细胞用于HLA-A*11:01阳性的胰腺癌、胃癌等患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT03412877 / NCI-2018-03627

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

AI 简述这是一项II期试验，研究基因工程T细胞用于多种转移性癌症。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Metastatic Digestive System Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT03539822 / NCI-2019-00380

Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies

AI 简述这是一项I/II期试验，研究Cabozantinib联合Durvalumab加或不加Tremelimumab用于胃癌、食管腺癌等消化道肿瘤。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT03516708 / NCI-2019-01785

Epacadostat with Standard Chemoradiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer

AI 简述这是一项I/II期试验，研究Epacadostat联合标准放化疗用于局部晚期直肠癌。在美国开展。

?

适用疾病: Stage I Rectal Cancer；Stage II Rectal Cancer；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 2

NCI NCT03935893 / NCI-2019-06773

Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers

AI 简述这是一项II期试验，研究细胞疗法用于局部晚期、转移性或复发性实体瘤，在美国开展。

?

适用疾病: Recurrent Merkel Cell Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2

NCI NCT04779554 / NCI-2021-01456

Flat Dose or Weight-Based Dose of Mitomycin during Cytoreductive Surgery for the Treatment of Advanced Gastrointestinal Malignancy

AI 简述这是一项II期试验，比较扁平剂量与基于体重的丝裂霉素剂量在细胞减灭术中对晚期胃肠道恶性肿瘤的治疗，在美国开展。

?

适用疾病: Advanced Malignant Digestive System Neoplasm；Peritoneal Carcinomatosis；Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: University of Kentucky/Markey Cancer Center

正在招募 Phase 2

NCI NCT04759664 / NCI-2021-07526

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

AI 简述这是一项II期试验，研究LUT014用于转移性结直肠癌患者EGFR抑制剂相关痤疮样皮疹。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: Lutris Pharma Ltd.

正在招募 Phase 2

NCI NCT05062317 / NCI-2021-10706

ctDNA-Directed Chemotherapy after Hepatectomy for the Treatment of Colorectal Liver Metastases

AI 简述这是一项2期试验，研究ctDNA指导的化疗用于结直肠癌肝转移切除术后，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Colon Cancer；Stage IV Rectal Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04421820 / NCI-2021-14002

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

AI 简述这是一项I/II期试验，研究BOLD-100联合FOLFOX用于晚期实体瘤，在美国、加拿大、德国、爱尔兰等地开展。

?

适用疾病: Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Bold Therapeutics, Inc.

正在招募 Phase 2

NCI NCT05254327 / NCI-2022-03371

Standard Chemotherapy and Short or Long Course Radiation Therapy with or without BMX-001 for the Treatment of Stage II-III Rectal Cancer

AI 简述这是一项II期试验，在II-III期直肠癌中比较标准放化疗联合或不联合BMX-001。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Nebraska Medical Center

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 2

NCI NCT05453825 / NCI-2022-07031

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

AI 简述这是一项II期试验，研究Navicixizumab单药或联合用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: OncXerna Theraputics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05533697 / NCI-2022-07826

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究mRNA-4359单用或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: ModernaTX, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04903873 / NCI-2022-08794

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，评估一种研究药物用于晚期实体瘤，包括结直肠癌等。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eutilex

正在招募 Phase 1, Phase 2

NCI NCT05394103 / NCI-2022-10300

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CDK7抑制剂Q901用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Qurient Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05592626 / NCI-2023-00103

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 1, Phase 2

NCI NCT04969315 / NCI-2023-03874

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

AI 简述这是一项I/II期试验，研究TT-10和TT-4单药或联合用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Portage Biotech

正在招募 Phase 2

NCI NCT05969860 / NCI-2023-05420

At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls

AI 简述这是一项II期试验，比较在家与在医院进行癌症治疗用于晚期癌症患者。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Head and Neck Cancer；Advanced Melanoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05669430 / NCI-2023-06313

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究GV20-0251单药或联合Pembrolizumab用于多种晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colon Cancer
干预: 未列出
地点: United States
申办方: GV20 Therapeutics

正在招募 Phase 2

NCI NCT06101277 / NCI-2023-09052

Local Ablative Therapy for the Treatment of Oligo-progressive Gastrointestinal Cancers, The LIVELONG Trial

AI 简述这是一项II期试验，在美国研究局部消融疗法用于寡进展性胃肠道癌症。

?

适用疾病: Metastatic Digestive System Cancer；Stage IV Small Intestinal Adenocarcinoma；Stage IV Appendix Cancer
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06307548 / NCI-2024-01256

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients with Locally Advanced or Recurrent Colorectal Cancer

AI 简述这是一项I/II期试验，在美国开展，研究荧光图像引导手术联合光动力疗法用于局部晚期或复发性结直肠癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Locally Advanced Colorectal Carcinoma；Recurrent Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2

NCI NCT06369259 / NCI-2024-03302

Avutometinib, Defactinib and Cetuximab for the Treatment of Patients with Unresectable or Metastatic, Refractory Colorectal Cancer

AI 简述这是一项II期试验，研究Avutometinib、Defactinib和西妥昔单抗用于不可切除或转移性难治性结直肠癌。

?

适用疾病: Stage III Colon Cancer；Stage IV Colon Cancer；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06385925 / NCI-2024-04303

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

AI 简述这是一项I/II期试验，研究TSN1611用于KRAS G12D突变晚期实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Tyligand Pharmaceuticals (Suzhou) Limited

正在招募 Phase 1, Phase 2

NCI NCT06399757 / NCI-2024-04491

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究APL-5125用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 1, Phase 2

NCI NCT06428409 / NCI-2024-05760

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

AI 简述这是一项I/II期试验，研究MK-2870单用或联合其他治疗用于胃肠癌，在美国、澳大利亚、加拿大、智利等地开展。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1, Phase 2

NCI NCT06055439 / NCI-2024-07692

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

AI 简述这是一项1/2期试验，研究CHM-2101 CAR-T细胞用于神经内分泌肿瘤、结直肠癌、胃癌等实体瘤。

?

适用疾病: Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Chimeric Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06598371 / NCI-2024-07763

Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究基因工程肿瘤浸润淋巴细胞KSQ-004EX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06598007 / NCI-2024-07992

A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CT3001单用或联合FOLFOX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Crossignal Therapeutics, Inc.

正在招募 Phase 2

NCI NCT06651593 / NCI-2024-08852

Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer

AI 简述这是一项II期试验，在美国研究SAR444881联合Cemiplimab用于晚期非小细胞肺癌、结直肠癌或卵巢癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06349590 / NCI-2024-09390

A Standardized Diet before Colorectal Cancer Surgery for the Prevention of Colorectal Cancer Recurrence and Metastasis after Surgery in Patients with Colorectal Cancer, The DIET Trial

AI 简述这是一项I/II期试验，研究标准化饮食用于预防结直肠癌术后复发转移。在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Resectable Colorectal Adenocarcinoma；Metastatic Resectable Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06268015 / NCI-2024-09836

Botensilimab and Balstilimab with Combination Chemotherapy for the Treatment of Patients with Metastatic Microsatellite Stable Colorectal Cancer

AI 简述这是一项II期试验，研究Botensilimab和Balstilimab联合化疗用于转移性微卫星稳定结直肠癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Microsatellite Stable Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募 Phase 1, Phase 2

NCI NCT06596694 / NCI-2025-00174

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

AI 简述这是一项I/II期试验，研究Patritumab Deruxtecan用于胃肠道癌症，在美国开展。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT06006923 / NCI-2025-00880

Regorafenib in Combination with Pembrolizumab or Pembrolizumab Alone for the Treatment of Metastatic or Unresectable MSI-H Colorectal Cancer

AI 简述这是一项II期试验，比较Regorafenib联合Pembrolizumab与Pembrolizumab单药用于转移性或不可切除MSI-H结直肠癌。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Unresectable Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT06730750 / NCI-2025-02617

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986490联合或不联合贝伐珠单抗用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2

NCI NCT06638502 / NCI-2025-02635

Safety of HRX215 in Patients After Minor and Major Liver Resection

AI 简述这是一项I/II期试验，研究HRX215在肝切除患者中的安全性，涉及结直肠癌肝转移。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: HepaRegeniX GmbH

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06885034 / NCI-2025-05982

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

AI 简述这是一项I/II期试验，研究GSK5764227单药或联合用于晚期胃肠癌。

?

适用疾病: Stage III Colon Cancer；Stage IV Colon Cancer；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: GlaxoSmithKline

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 2

NCI NCT07082439 / NCI-2025-06736

Pembrolizumab in Combination with Odetiglucan for the Treatment of Patients with Metastatic Colorectal Cancer with Liver Metastases

AI 简述这是一项II期试验，研究Pembrolizumab联合Odetiglucan用于转移性结直肠癌肝转移，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 2

NCI NCT06669572 / NCI-2025-06973

Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer

AI 简述这是一项II期试验，研究Lenvatinib联合Pembrolizumab用于不可切除肛管直肠鳞状细胞癌，在美国开展。

?

适用疾病: Stage III Anal Cancer；Stage IV Anal Cancer；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06569368 / NCI-2025-07395

Metronidazole to Reduce the Tumor Associated Bacteria of Rectal Adenocarcinoma in Patients Receiving Neoadjuvant Therapy

AI 简述这是一项II期试验，研究甲硝唑用于减少直肠腺癌的肿瘤相关细菌，在美国开展。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07197827 / NCI-2025-07559

A Study of YL242 in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL242用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT07205718 / NCI-2025-08225

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-188用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT06725758 / NCI-2025-08359

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

AI 简述这是一项I/II期试验，在美国开展，研究ODM-212用于晚期实体瘤。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Orion Corporation, Orion Pharma

正在招募 Phase 2

NCI NCT07227636 / NCI-2025-08584

Botensilimab and Balstilimab for the Treatment of Colorectal Cancer in Patients with Persistent Circulating Tumor Deoxyribonucleic Acid following Surgery and Chemotherapy

AI 简述这是一项II期试验，研究Botensilimab和Balstilimab用于III期结直肠癌术后化疗后ctDNA持续阳性的患者。

?

适用疾病: Stage III Colon Cancer；Stage III Rectal Cancer；Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07145255 / NCI-2026-00044

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究ADC用于多种晚期难治实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT07411599 / NCI-2026-00995

Intraperitoneal and Intravenous TROP2 CAR/IL-15 TGFBR2 KO NK Cell Therapy with Cetuximab for the Treatment of Microsatellite Stable Colorectal Cancer with Peritoneal Metastases, Chip-CRC Trial

AI 简述这是一项I/II期试验，研究TROP2 CAR-NK细胞联合西妥昔单抗用于微卫星稳定结直肠癌腹膜转移。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Microsatellite Stable Colorectal Carcinoma；Unresectable Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT07235293 / NCI-2026-01355

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

AI 简述这是一项II期试验，在美国研究DSP107联合Atezolizumab对比Fruquintinib用于晚期结直肠癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Advanced Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: Kahr Bio Australia Pty Ltd

正在招募 Phase 2

NCI NCT07415031 / NCI-2026-02775

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

AI 简述这是一项II期试验，用于既往参与adagrasib研究的晚期实体瘤患者长期治疗，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Lung Cancer；Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Mirati Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT07436728 / NCI-2026-03048

A Study of TAK-505 in Adults With Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-505用于晚期实体瘤，包括头颈癌、非小细胞肺癌等。在美国开展。

?

适用疾病: Metastatic Head and Neck Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT07186842 / NCI-2026-03238

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

AI 简述这是一项I/II期试验，研究BNT329用于晚期实体瘤（表达CA19-9）。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT07335497 / NCI-2026-03444

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究CR-001用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Crescent Biopharma, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Colorectal Cancer；Metastatic Pancreatic Cancer；Metastatic Ovarian Cancer
干预: Pembrolizumab (Keytruda)，Fludarabine，Cyclophosphamide，Aldesleukin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT02185443

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

AI 简述这是一项II期试验，研究立体定向体部放疗用于不可切除的肝转移瘤，在巴西开展。

?

适用疾病: Liver Metastases；Colorectal Cancer；Anal Canal Cancer
干预: SBRT
地点: Brazil
申办方: University of Sao Paulo

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03401294

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

AI 简述这是一项II期试验，研究FOLFOXIRI联合贝伐珠单抗用于不可切除转结直肠癌的转化治疗。

?

适用疾病: Metastatic Colorectal Cancer
干预: FOLFOXIRI and Bevacizumab
地点: Canada
申办方: University of Saskatchewan

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT03526835 / NCI-2021-03548

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究双特异性抗体MCLA-158用于晚期实体瘤。在美国、比利时、法国、荷兰等开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Colorectal Cancer；Gastric Cancer
干预: MCLA-158，MCLA-158 + Pembrolizumab，MCLA-158 + FOLFIRI，MCLA-158 + FOLFOX
地点: United States，Belgium，France，Netherlands 等 2 个
申办方: Merus B.V.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03947385 / NCI-2019-04523

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

AI 简述这是一项I/II期试验，研究IDE196用于GNAQ/11突变或PRKC融合的实体瘤，在美国、澳大利亚、加拿大开展。

?

适用疾病: Metastatic Uveal Melanoma；Cutaneous Melanoma；Colorectal Cancer
干预: IDE196，Binimetinib，Crizotinib
地点: United States，Australia，Canada
申办方: IDEAYA Biosciences

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT03965234 / NCI-2019-02940

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

AI 简述这是一项I/II期试验，研究肺灌注控制肉瘤或结直肠癌肺转移的微小残留病灶。在美国开展。

?

适用疾病: Metastatic Bone Sarcoma；Metastatic Malignant Neoplasm in the Lung；Metastatic Soft Tissue Sarcoma
干预: Cisplatin，Isolated Chemotherapeutic Lung Perfusion，Metastasectomy
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04014530

Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

AI 简述这是一项I/II期试验，研究Pembrolizumab联合Ataluren用于转移性结直肠癌或子宫内膜癌。

?

适用疾病: Colorectal Cancer；Endometrium Cancer
干预: Ataluren + Pembrolizumab
地点: Netherlands
申办方: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04109755

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合放疗用于局部MSS直肠癌。

?

适用疾病: Rectum Cancer；Rectal Cancer
干预: Pembrolizumab
地点: Switzerland
申办方: University Hospital, Geneva

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

AI 简述这是一项I/II期试验，研究rezatapopt用于TP53 Y220C突变晚期实体瘤，在美澳法德开展。

?

适用疾病: Advanced Solid Tumor；Advanced Malignant Neoplasm；Metastatic Cancer
干预: rezatapopt，pembrolizumab
地点: United States，Australia，France，Germany 等 5 个
申办方: PMV Pharmaceuticals, Inc

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04657068 / NCI-2021-04129

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究ART0380联合吉西他滨或伊立替康用于晚期或转移性实体瘤。

?

适用疾病: Advanced Cancer；Metastatic Cancer；Ovarian Cancer
干预: ART0380，Gemcitabine，Irinotecan
地点: United States，France，Spain，United Kingdom
申办方: Artios Pharma Ltd

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04689347

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

AI 简述这是一项I/II期试验，研究5FU/LV、伊立替康、替莫唑胺和贝伐珠单抗用于MGMT沉默、微卫星稳定转移性结直肠癌，在意大利开展。

?

适用疾病: Metastatic Colorectal Cancer
干预: Bevacizumab，Irinotecan，Leucovorin，5Fluorouracil
地点: Italy
申办方: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04701476 / NCI-2021-11336

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

AI 简述这是一项II期试验，研究TATE联合Pembrolizumab用于转移性结直肠癌和非小细胞肺癌，在美国和台湾开展。

?

适用疾病: Colorectal Cancer; Lung Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage IVA Colorectal (Colon or Rectal) Cancer
干预: TATE and pembrolizumab，TAS-102 pill，Regorafenib Pill
地点: United States，Taiwan
申办方: Teclison Ltd.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04771520 / NCI-2021-00702

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

AI 简述这是一项II期试验，研究Avapritinib用于CKIT或PDGFRA突变阳性晚期实体瘤。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Avapritinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04895709 / NCI-2021-06088

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物其他放疗

ClinicalTrials.gov NCT04899908

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

AI 简述这是一项II期试验，研究立体定向脑部放疗联合AGuIX钆基纳米颗粒用于脑转移瘤，来自肺癌、乳腺癌、黑色素瘤等。

?

适用疾病: Brain Cancer；Brain Metastases；Melanoma
干预: Stereotactic Radiation，AGuIX gadolinium-based nanoparticles，Placebo
地点: United States
申办方: Brigham and Women's Hospital

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05007132

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

AI 简述这是一项II期试验，头对头比较Trifluridine/Tipiracil联合Panitumumab或Bevacizumab一线治疗转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Panitumumab 20 milligram/ML，Bevacizumab，Trifluridine/Tipiracil Hydrochloride
地点: Germany
申办方: Dominik Paul Modest

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov NCT05093907

A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

AI 简述这是一项I/II期试验，研究BEY1107联合卡培他滨用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: BEY1107，Capecitabine
地点: South Korea
申办方: BeyondBio Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05136326

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

AI 简述这是一项II期试验，研究术前卡培他滨和替莫唑胺联合放疗用于MGMT沉默、MSS的局部晚期直肠癌，在意大利开展。

?

适用疾病: Rectal Cancer
干预: External-beam radiation，Capecitabine，Temozolomide
地点: Italy
申办方: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05239546

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

AI 简述这是一项II期试验，研究Dostarlimab新辅助治疗II和III期错配修复缺陷结肠癌。

?

适用疾病: Colon Cancer；dMMR Colorectal Cancer
干预: Dostarlimab
地点: United States
申办方: University of Iowa

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov NCT05250648

Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

AI 简述这是一项IV期试验，研究丝裂霉素C腹腔热灌注化疗（HIPEC）用于结肠癌腹膜转移。

?

适用疾病: Peritoneal Carcinomatosis；Colon Cancer
干预: complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes，complete cytoreductive surgery without HIPEC
地点: Spain
申办方: Hospital Universitario de Fuenlabrada

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT05286814 / NCI-2022-02511

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

AI 简述这是一项II期试验，研究PDS01ADC联合肝动脉灌注泵和全身治疗用于转移性结直肠癌、肝内胆管癌或转移性肾上腺皮质癌。

?

适用疾病: Metastatic Colorectal Cancer (Mcrc)；Intrahepatic Cholangiocarcinoma (Icc)；Intrahepatic Bile Duct Cancer
干预: Dexamethasone，PDS01ADC，Intera 3000 Hepatic Artery Infusion Pump (HAIP)，Floxuridine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05296681

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

AI 简述这是一项II期试验，研究NBT-NM108用于IV期结肠癌，在美国开展。

?

适用疾病: Metastatic Colon Carcinoma；Stage IV Colon Cancer AJCC v8；Stage IVA Colon Cancer AJCC v8
干预: NBT-NM108
地点: United States
申办方: Howard S. Hochster, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05310643

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

AI 简述这是一项2期试验，在法国研究Nivolumab和Ipilimumab用于抗PD-1耐药的dMMR/MSI转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Nivolumab，Ipilimumab
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05319314 / NCI-2022-04176

LYL273 for Patients With Relapsed or Refractory mCRC

AI 简述这是一项I/II期试验，研究LYL273用于复发或难治性转移性结直肠癌。

?

适用疾病: Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Colorectal Cancer
干预: LYL273
地点: United States
申办方: Lyell Immunopharma, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

AI 简述这是一项I/II期试验，研究RMC-6236用于携带特定RAS突变的晚期实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05462236

MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Tinodasertib联合Pembrolizumab或Irinotecan用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Tinodasertib，Pembrolizumab，Irinotecan
地点: Australia
申办方: AUM Biosciences Pte Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05672524 / NCI-2023-00109

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

AI 简述这是一项II期试验，研究Tucatinib和Trastuzumab用于HER2阳性直肠癌。

?

适用疾病: Adenocarcinoma of the Rectum；Locally Advanced Rectal Adenocarcinoma；Rectal Adenocarcinoma
干预: Trastuzumab，Tucatinib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT05691491 / NCI-2022-10211

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

AI 简述这是一项I/II期试验，研究Temozolomide和M1774用于晚期恶性实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Neoplasm；Advanced Microsatellite Stable Colorectal Carcinoma；Hematopoietic and Lymphatic System Neoplasm
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05700656

Galunisertib Combined With Capecitabine in Advanced CRC With PM

AI 简述这是一项I/II期试验，在荷兰研究Galunisertib联合卡培他滨用于结直肠癌腹膜转移。

?

适用疾病: Colorectal Cancer Metastatic；Peritoneal Carcinomatosis
干预: Galunisertib plus capecitabine
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05706129

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究[68Ga]Ga-DPI-4452和[177Lu]Lu-DPI-4452用于多种晚期实体瘤。在澳大利亚、法国等地开展。

?

适用疾病: Clear Cell Renal Cell Cancer (ccRCC)；Pancreatic Ductal Adenocarcinoma (PDAC)；Colorectal Cancer (CRC)
干预: [68Ga]Ga-DPI-4452，[177Lu]Lu-DPI-4452
地点: Australia，France
申办方: ITM Oncologics GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05706779

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

AI 简述这是一项II期试验，研究Encorafenib联合Cetuximab用于BRAF V600E突变局限性结肠或上直肠癌的新辅助治疗。

?

适用疾病: Colorectal Cancer；BRAF V600E Mutation Positive
干预: Encorafenib Oral Capsule + Cetuximab
地点: France
申办方: Federation Francophone de Cancerologie Digestive

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05725200

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Alectinib、西妥昔单抗等个体化治疗用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Alectinib，Cetuximab，Crizotinib，Dasatinib
地点: Norway
申办方: Oslo University Hospital

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05733000

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

AI 简述这是一项2期试验，研究Devimistat联合羟氯喹和氟尿嘧啶或吉西他滨用于晚期难治性实体瘤。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Colorectal Carcinoma；Advanced Gastroesophageal Junction Adenocarcinoma
干预: Biospecimen Collection，Computed Tomography，Devimistat，Fluorouracil
地点: United States
申办方: Northwestern University

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT05759728

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

AI 简述这是一项1/2期试验，研究CNA3103（LGR5靶向CAR-T）用于转移性结直肠癌。

?

适用疾病: Colorectal Cancer Metastatic
干预: CNA3103: 5 x 10^7 cells，CNA3103: 1.5 x 10^8 cells，CNA3103: 4.5 x 10^8 cells，CNA3103: 1.5 x 10^9 cells
地点: Australia
申办方: Carina Biotech Limited

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT05775146

SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases

AI 简述这是一项II期试验，研究立体定向体部放疗用于结直肠癌新辅助治疗后肝转移，在加拿大开展。

?

适用疾病: Colorectal Cancer；Liver Metastasis Colon Cancer
干预: stereotactic body radiation treatment (SBRT)
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05786924 / NCI-2023-03966

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

AI 简述这是一项I/II期试验，研究S241656用于RAS/MAPK突变阳性恶性肿瘤。在美、丹、港、日等地开展。

?

适用疾病: Non-small Cell Lung Cancer；Histiocytic Neoplasm；Histiocytosis
干预: S241656，FOLFOX6/FOLFOX7，FOLFIRI，Cetuximab
地点: United States，Denmark，Hong Kong，Japan 等 1 个
申办方: Institut de Recherches Internationales Servier

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05806931 / NCI-2023-02841

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究TAS-102联合奥沙利铂或伊立替康加贝伐珠单抗用于晚期结直肠癌。

?

适用疾病: Colon Cancer；Rectal Cancer；Refractory Colorectal Cancer
干预: TAS-102, oxaliplatin, irinotecan with bevacizumab
地点: United States
申办方: Rutgers, The State University of New Jersey

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AI 简述这是一项I/II期试验，研究GI-102单药或联合其他药物用于晚期实体瘤。在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05854498 / NCI-2024-06017

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

AI 简述这是一项2期试验，研究脂质体伊立替康联合TAS102和贝伐珠单抗用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Liposomal irinotecan，TAS102，Bevacizumab
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05870800

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER

AI 简述这是一项II期试验，研究新辅助免疫化疗用于可切除的非转移性结肠癌。

?

适用疾病: Stage I Colon Cancer；Stage II Colon Cancer；Stage III Colon Cancer
干预: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2，Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2，Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05919264 / NCI-2023-06767

FOG-001 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚开展，研究FOG-001联合化疗或免疫治疗用于局部晚期或转移性实体瘤。

?

适用疾病: Cancer；Colorectal Cancer；Solid Tumor
干预: FOG-001，mFOLFOX-6，Nivolumab，Trifluridine/tipiracil
地点: United States，Australia
申办方: Parabilis Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06047379 / NCI-2024-08760

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AI 简述这是一项1/2期试验，研究NEO212用于星形细胞瘤、胶质母细胞瘤或脑转移瘤。在美国开展。

?

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06051695 / NCI-2024-01620

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，在美国开展，研究间皮素靶向逻辑门控CAR-T细胞用于表达MSLN且失去HLA-A*02表达的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；NSCLC
干预: A2B694，A2B543，xT CDx with HLA-LOH Assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

AI 简述这是一项1/2期试验，研究Elironrasib和Daraxonrasib单药或联合用于KRAS G12C突变实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer (NSCLC)；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: Elironrasib，Daraxonrasib
地点: United States，France，Germany，Italy 等 3 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT06130280 / NCI-2023-09876

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

AI 简述这是一项2期试验，研究单次MRI引导SBRT用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer；Liver Metastases；Stage IV Colorectal (Colon or Rectal) Cancer
干预: MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06149481 / NCI-2023-10471

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

AI 简述这是一项I/II期试验，研究SX-682、TriAdeno疫苗、Retifanlimab和N-803联合用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: Retifanlimab，Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform，N-803，SX-682
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06205836 / NCI-2024-10236

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

AI 简述这是一项II期试验，研究Cemiplimab联合或不联合Fianlimab用于早期MSI-H结直肠癌。

?

适用疾病: Colorectal Cancer；Stage I Colorectal (Colon or Rectal) Cancer；Stage II Colorectal (Colon or Rectal) Cancer
干预: Cemiplimab，Fianlimab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06207656

Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer

AI 简述这是一项2期试验，研究Cetuximab联合Encorafenib和Binimetinib用于BRAF V600E突变、MSS型可切除或潜在可切除晚期结直肠癌。

?

适用疾病: Colorectal Cancer
干预: EBC
地点: Spain
申办方: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

正在招募 Phase 2 生物制剂联合产品

ClinicalTrials.gov NCT06225843

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

AI 简述这是一项II期试验，研究Sotevtamab联合FOLFOX用于结直肠癌肝转移。在加拿大开展。

?

适用疾病: Metastatic Colorectal Cancer
干预: Sotevtamab，FOLFOX
地点: Canada
申办方: Alethia Biotherapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06244771

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究FMC-376用于KRAS G12C突变的晚期实体瘤。

?

适用疾病: Advanced Solid Tumors With KRAS G12C Mutations；Solid Tumor, Adult；Unresectable Solid Tumor
干预: FMC-376
地点: United States，Australia，South Korea
申办方: Frontier Medicines Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06245356

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

AI 简述这是一项II期试验，在法国研究Lonsurf用于二氢嘧啶脱氢酶缺乏的转移性结直肠癌或胃食管腺癌。

?

适用疾病: Metastatic Colorectal Cancer；Metastatic Gastroesophageal Adenocarcinoma；DPD Deficiency
干预: Lonsurf，Oxaliplatin，Panitumumab，Bevacizumab
地点: France
申办方: UNICANCER

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究GM103瘤内注射用于多种晚期实体瘤。

?

适用疾病: Head and Neck Cancer；Malignant Melanoma；Colorectal Cancer
干预: GM103 (Part A)，GM103 (Part B)，GM103 and Pembrolizumab (Part C)
地点: South Korea
申办方: GeneMedicine Co., Ltd.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06300463

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

AI 简述这是一项II期试验，研究免疫治疗组合用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer Metastatic；Liver Metastases；Colorectal Cancer
干预: Botensilimab，Balstilimab，AGEN1423，Radiation
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06362369 / NCI-2024-03436

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

AI 简述这是一项I/II期试验，研究Alintegimod联合Ipilimumab及Nivolumab用于晚期实体瘤。

?

适用疾病: Advanced Cancer；Advanced Solid Tumor；Melanoma
干预: Alintegimod，Ipilimumab，Nivolumab
地点: United States
申办方: 7 Hills Pharma, LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究PARG抑制剂ETX-19477用于晚期实体恶性肿瘤。在美国开展。

?

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06411600

Combination Therapy for BRAF-V600E Metastatic CRCm

AI 简述这是一项II期试验，研究Encorafenib、Cetuximab、Bevacizumab用于BRAF-V600E突变转移性结直肠癌，在西班牙开展。

?

适用疾病: Metastatic Colorectal Cancer
干预: Encorafenib，Cetuximab，Bevacizumab
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06412198 / NCI-2024-04127

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

AI 简述这是一项I/II期试验，研究Adagrasib、Cetuximab、Cemiplimab用于KRAS G12C突变转移性结直肠癌，在美国开展。

?

适用疾病: Metastatic Colorectal Cancer；KRAS G12C Mutations；Stage III Colorectal (Colon or Rectal) Cancer
干预: Cetuximab，Cemiplimab，Adagrasib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06445062 / NCI-2024-05164

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

AI 简述这是一项I/II期试验，研究RMC-6236联合化疗用于胃肠道实体瘤。

?

适用疾病: Colorectal Cancer；CRC；Pancreatic Ductal Adenocarcinoma
干预: RMC-6236，mFOLFOX6 regimen，bevacizumab，mFOLFIRINOX regimen
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06475352

Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

AI 简述这是一项II期试验，研究FOLFOX或CAPOX方案用于缺乏特定肝酶的胃肠癌患者，在法国开展。

?

适用疾病: Digestive Cancer；Colorectal Cancer
干预: FOLFOX regimen，CAPOX regimen
地点: France
申办方: UNICANCER

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT06522919

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合树突状细胞疫苗序贯Trifluridine/Tipiracil加Bevacizumab用于难治性pMMR/MSS转移性结直肠癌，在意大利开展。

?

适用疾病: Colorectal Cancer Metastatic；Microsatellite Stable Colorectal Carcinoma；Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
干预: Autologous Dendritic Cell (DC) Vaccine
地点: Italy
申办方: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06529523 / NCI-2024-06531

Tislelizumab in People With Colorectal Cancer

AI 简述这是一项2期试验，研究Tislelizumab用于结直肠癌，在美国和尼日利亚开展。

?

适用疾病: Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Rectal Cancer
干预: Tislelizumab
地点: United States，Nigeria
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06553885 / NCI-2024-09177

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

AI 简述这是一项II期试验，在美国开展，研究Enfortumab Vedotin用于晚期或转移性结直肠癌或肝细胞癌。

?

适用疾病: Metastatic Colorectal Cancer；Hepatocellular Carcinoma；Stage III Colorectal (Colon or Rectal) Cancer
干预: Enfortumab Vedotin
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 联合产品

ClinicalTrials.gov NCT06555133

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

AI 简述这是一项II期试验，在美国开展，研究Y-90放射栓塞联合卡培他滨和阿替利珠单抗用于寡转移结直肠癌肝转移。

?

适用疾病: Colorectal Carcinoma Metastatic in the Liver
干预: yttrium-90 radioembolization
地点: United States
申办方: Brown University

正在招募 Phase 4 药物

ClinicalTrials.gov / NCI NCT06562543 / NCI-2025-00409

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

AI 简述这是一项IV期试验，研究Fruquintinib用于晚期经治结直肠癌的少数群体。

?

适用疾病: Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Metastatic Colorectal Adenocarcinoma
干预: Fruquintinib
地点: United States，Puerto Rico
申办方: Takeda

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT06563986

FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer

AI 简述这是一项II期试验，在荷兰等地研究FTD-TPI联合Bevacizumab及166Ho微球放射栓塞用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Systemic treatment (FTD-TPI and bevacizumab)，Radioembolization with 166-Ho microspheres
地点: Netherlands
申办方: UMC Utrecht

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06589440 / NCI-2026-00465

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

AI 简述这是一项II期试验，研究SR-8541A联合Botensilimab和Balstilimab用于难治性转移性微卫星稳定结直肠癌，在美国开展。

?

适用疾病: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)；Stage III Colon Cancer；Stage IV Colon Cancer
干预: SR-8541A
地点: United States
申办方: Stingray Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06607458 / NCI-2025-05249

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

AI 简述这是一项II期试验，在美国、捷克等地研究肝动脉高剂量美法仑后联合曲氟尿苷替匹嘧啶和贝伐珠单抗用于肝转移为主的难治性结直肠癌。

?

适用疾病: Refractory Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab，Trifluridine-tipiracil plus Bevacizumab Alone
地点: United States，Czechia，Germany，Italy 等 4 个
申办方: Delcath Systems Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06630624

Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

AI 简述这是一项I/II期试验，研究IP-001在微波消融或不可逆电穿孔后用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer；Liver Metastases；Liver Metastasis Colon Cancer
干预: IP-001
地点: Netherlands
申办方: M.R. Meijerink

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06634875 / NCI-2025-01768

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

AI 简述这是一项II期试验，在美国研究Isunakinra单用或联合Pembrolizumab用于MSS结直肠癌。

?

适用疾病: Colorectal Cancer Metastatic；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: isunakinra
地点: United States
申办方: Buzzard Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06640166

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

AI 简述这是一项II期试验，研究Encorafenib+Cetuximab联合FOLFIRI用于BRAF V600E突变转移性结直肠癌。

?

适用疾病: Colorectal Carcinoma；Colorectal Neoplasms；Colorectal Tumor
干预: encorafenib + cetuximab + FOLFIRI
地点: Italy
申办方: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06680739

Single cEll pRofiling PErsistaNce To ImmuNothErapy

AI 简述一项II期试验，研究Durvalumab和Tremelimumab用于结直肠癌和子宫内膜癌。

?

适用疾病: Colorectal Cancer；Endometrial Cancer
干预: Durvalumab，Tremelimumab
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06682793 / NCI-2025-01614

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，研究A2B395（一种CAR-T）用于表达EGFR且HLA-A*02缺失的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；Non-Small Cell Lung
干预: A2B395，xT CDx with HLA-LOH assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06695845

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

AI 简述这是一项2期试验，研究Zanidatamab用于HER2表达肿瘤，在美国、韩国、西班牙等地开展。

?

适用疾病: Breast Cancer；Gastric Cancer；Esophageal Cancer
干预: Zanidatamab
地点: United States，South Korea，Spain
申办方: Jazz Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06714357

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

AI 简述这是一项II期试验，研究丙戊酸联合伊立替康和帕尼单抗用于转移性结直肠癌。

?

适用疾病: Colorectal Cancer Metastatic
干预: irinotecan，panitumumab，Valproic Acid (VPA)
地点: Italy
申办方: National Cancer Institute, Naples

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06728072 / NCI-2024-10463

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

AI 简述这是一项II期试验，在标准治疗化疗基础上加用抗生素用于IV期结直肠癌。

?

适用疾病: Colorectal Cancer；CRC；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
地点: United States
申办方: Virginia Commonwealth University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06820463 / NCI-2025-02761

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

AI 简述这是一项II期试验，在美国、澳大利亚等地开展，研究Telisotuzumab Adizutecan联合化疗用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: Telisotuzumab Adizutecan，Fluorouracil，Oxaliplatin，Leucovorin
地点: United States，Australia，Austria，Brazil 等 9 个
申办方: AbbVie

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06824064

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

AI 简述这是一项II期试验，研究RBS2418用于晚期转移性结直肠癌，在美国、波多黎各、越南等地开展。

?

适用疾病: Metastatic Colorectal Cancer；Advanced Colorectal Cancer
干预: RBS2418，Placebo
地点: United States，Puerto Rico，Vietnam
申办方: Riboscience, LLC.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06856837

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

AI 简述这是一项II期试验，研究呋喹替尼联合替雷利珠单抗用于MSS/pMMR转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Fruquintinib，Tislelizumab，Trifluridine/tipiracil，Bevacizumab
地点: Austria，Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06873763

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

AI 简述这是一项1/2期试验，研究Nelmastobart联合化疗和贝伐珠单抗用于转移性或复发性结直肠癌，在韩国开展。

?

适用疾病: Metastatic Colorectal Cancer (CRC)；Recurrent Colorectal Cancer
干预: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
地点: South Korea
申办方: STCube, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06887218

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Regorafenib联合5FU/LV用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)
干预: Regorafenib (BAY 73-4506)，5FU/LV，Bevacizumab，Trifluridine-tipiracil
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 1, Phase 2 药物其他

ClinicalTrials.gov NCT06922383

A Clinical Study of Arfolitixorin in Patients With mCRC

AI 简述这是一项I/II期试验，研究Arfolitixorin用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (mCRC)
干预: Arfolitixorin，Leucovorin
地点: Germany
申办方: Isofol Medical AB

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06934538

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

AI 简述这是一项I/II期试验，研究STC-1010联合免疫治疗与标准治疗用于不可切除晚期结直肠癌。

?

适用疾病: Unresectable Metastatic Colorectal Cancer；Unresectable Locally Advanced Colorectal Cancer
干预: STC-1010 + IS regimen + SOC therapy
地点: United States，Belgium，France
申办方: Brenus Pharma

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06937177 / NCI-2025-04661

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Colorectal Cancer Undergoing Chemotherapy

AI 简述这是一项II期试验，研究TCMCB07用于优化新诊断结直肠癌化疗患者的体重。

?

适用疾病: Cancer Weight Loss；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: TCMCB07，Placebo
地点: United States，Canada
申办方: Endevica Bio

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06948448 / NCI-2025-06039

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

AI 简述这是一项II期试验，评估ONO-4578联合Opdivo及mFOLFOX6/贝伐珠单抗用于非MSI-H/dMMR、PD-L1阳性晚期结直肠癌。在美国等地开展。

?

适用疾病: Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: ONO-4578，Opdivo®，Oxaliplatin，5-Fluorouracil
地点: United States，Canada，France，Italy 等 2 个
申办方: Ono Pharmaceutical Co., Ltd.

正在招募 Phase 2 联合产品药物

ClinicalTrials.gov NCT06949982

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

AI 简述这是一项II期试验，在俄罗斯开展，比较羟氯喹联合甲氨蝶呤、卡培他滨和贝伐珠单抗与瑞戈非尼用于RAS突变难治性转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (mCRC)；Colorectal Neoplasms
干预: experimental group x-MAP，Regorafenib (BAY 73-4506)
地点: Russia
申办方: Sergey Orlov, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06959550 / NCI-2025-03211

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究依沃西单抗（抗PD-1/VEGF双抗）用于既往治疗过的转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Ivonescimab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06992258 / NCI-2025-09077

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

AI 简述这是一项二期试验，比较呋喹替尼联合TAS-102与呋喹替尼单药用于难治性晚期/转移性结直肠癌。

?

适用疾病: Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Fruquintinib+ Lonsurf (trifluridine and tipiracil)，Fruquintinib
地点: United States
申办方: Criterium, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07011576

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

AI 简述这是一项II期试验，研究Fruquintinib联合FOLFIRI用于转移性结直肠癌的二线治疗，在美国开展。

?

适用疾病: Colon Cancer；Rectal Cancer；Colorectal Cancer
干预: fruquintinib，FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
地点: United States
申办方: SCRI Development Innovations, LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07020221 / NCI-2025-04955

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究VS-7375用于KRAS G12D突变实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non Small Cell Lung Cancer；Colorectal Cancer
干预: VS-7375，Cetuximab，Carboplatin + Pemetrexed + Pembrolizumab，Gemcitabine
地点: United States，Australia
申办方: Verastem, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07030257 / NCI-2025-08127

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项1/2期试验，研究CP-383用于晚期或转移性实体瘤，包括结直肠癌、小细胞肺癌等。

?

适用疾病: Solid Tumor Malignancies；Colorectal Carcinoma；Small Cell Lung Cancer ( SCLC )
干预: CP-383
地点: United States
申办方: Tasca Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07042685

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究呋喹替尼联合化疗用于局部晚期不可切除或转移性结直肠癌，在美国开展。

?

适用疾病: Metastatic Colorectal Cancer (CRC)
干预: Fruquintinib Combined With Chemotherapy
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07079631 / NCI-2025-06037

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

AI 简述这是一项I/II期试验，在美、德、日、西等国研究BNT314联合Pumitamig和化疗用于晚期结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage III Colon Cancer；Stage IV Colon Cancer
干预: BNT314，Pumitamig，SoC chemotherapy treatment 1，SoC chemotherapy treatment 2
地点: United States，Germany，Japan，Spain 等 1 个
申办方: BioNTech SE

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT07130903 / NCI-2025-06048

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

AI 简述这是一项II期试验，在美国研究调幅射频电磁场联合呋喹替尼用于难治性转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Metastatic Colorectal Adenocarcinoma
干预: Fruquintinib，TheraBionic P1
地点: United States
申办方: Barbara Ann Karmanos Cancer Institute

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07147231 / NCI-2025-06058

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

AI 简述这是一项I/II期试验，在美国研究Pidnarulex联合Cemiplimab用于难治性微卫星稳定结直肠癌。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Refractory Colorectal Adenocarcinoma；Stage III Colorectal Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Cemiplimab，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

AI 简述这是一项1/2a期试验，研究WEF-001用于晚期KRAS突变实体瘤。

?

适用疾病: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma；Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer；Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
干预: WEF-001
地点: United States，Canada，United Kingdom
申办方: Auricula Biosciences Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07169734 / NCI-2025-08325

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

AI 简述这是一项I/II期试验，研究ALE.P03用于CLDN1阳性晚期或转移性实体瘤。

?

适用疾病: Cervical Squamous Cell Carcinoma；Squamous Non-small-cell Lung Cancer；Colorectal Cancer
干预: ALE.P03
地点: United States，France，Hong Kong，Italy 等 4 个
申办方: Alentis Therapeutics AG

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07189871 / NCI-2026-03797

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-BetaBart用于复发/难治性局部晚期不可切除或转移性实体瘤。

?

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07192068

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

AI 简述这是一项II期试验，在France等地研究Zanidatamab用于HER2基因改变实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer；Sarcoma；Head &Amp; Neck Cancer
干预: Zanidatamab
地点: France
申办方: UNICANCER

正在招募 Phase 2 器械药物手术/操作

ClinicalTrials.gov / NCI NCT07201519 / NCI-2025-06968

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

AI 简述这是一项II期试验，研究肝动脉灌注化疗的混合模式用于转移性结直肠癌和胆管癌。

?

适用疾病: Colorectal Cancer Metastatic；Intrahepatic Cholangiocarcinoma；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Hepatic Artery Infusion Pump (HAIP)，Standard Treatment，Community Treatment，Systemic Chemotherapy Standard of Care
地点: United States
申办方: Michael J Cavnar, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07213570

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

AI 简述这是一项II期试验，在意大利研究Regorafenib用于RAS突变晚期结直肠癌的二线治疗。

?

适用疾病: Colorectal Cancer Metastatic
干预: standard second line treatment, at discretion of the investigator，Regorafenib (BAY73-4506)
地点: Italy
申办方: National Cancer Institute, Naples

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07213609 / NCI-2026-02611

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

AI 简述这是一项I/II期试验，在美国等地单独或联合研究GSK5460025用于多种晚期实体瘤。

?

适用疾病: Neoplasms, Colorectal；Neoplasms；Recurrent Malignant Solid Tumor
干预: GSK5460025
地点: United States，Canada，Japan，Netherlands 等 2 个
申办方: GlaxoSmithKline

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

AI 简述这是一项II期试验，研究患者对皮下与静脉注射免疫治疗的偏好。在美国开展。

?

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07244705

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

AI 简述这是一项I/II期试验，研究ABT-301联合Tislelizumab和Bevacizumab用于pMMR/非MSI-H晚期或转移性结直肠癌，在澳大利亚、台湾等地开展。

?

适用疾病: Colorectal Cancer (Diagnosis)；Colorectal Cancer Metastatic；Colorectal Cancer (CRC)
干预: ABT-301，Tislelizumab，Bevacizumab (Avastin)
地点: Australia，Taiwan
申办方: Anbogen Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07255664

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

AI 简述这是一项I/IIa期试验，在德国研究TIL免疫疗法用于转移性结直肠癌和前列腺癌。

?

适用疾病: Metastatic Colorectal Cancer；Prostate Cancer Metastatic；Prostate Cancer Locally Advanced
干预: CC-38，Pembrolizumab，Cyclophosphamid，Interleukin-2
地点: Germany
申办方: CuraCell TX AB

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07262619

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

AI 简述这是一项I/II期试验，研究EIK1005联合Pembrolizumab用于晚期实体瘤包括MSI-H肿瘤。

?

适用疾病: Advanced Solid Tumors；MSI-H or dMMR Advanced Solid Tumors；MSI-H/dMMR Gastric Cancer
干预: EIK1005，pembrolizumab (KEYTRUDA® )
地点: United States，Australia，New Zealand
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07281716 / NCI-2025-08760

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

AI 简述这是一项I/II期试验，研究Nadunolimab联合Toripalimab用于化疗难治性转移性MSS结直肠癌，在美国开展。

?

适用疾病: Metastatic Microsatellite Stable Colorectal Carcinoma；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Microsatellite Stable Colorectal Carcinoma
干预: Nadunolimab，Toripalimab
地点: United States
申办方: Dan Feng

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT07292298

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

AI 简述这是一项II期试验，在美国研究高剂量率直肠近距离放疗用于新辅助治疗后低位残留直肠腺癌。

?

适用疾病: Rectal Adenocarcinoma；Rectal Cancer
干预: High Rare Dose Rectal Brachytherapy Boost
地点: United States
申办方: University of Colorado, Denver

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07397338 / NCI-2026-01954

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

AI 简述这是一项I/II期试验，在美国研究Daraxonrasib、Elironrasib、Zoldonrasib联合Ivonescimab用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumors；Metastatic Solid Tumors；Non-small Cell Lung Cancer (NSCLC)
干预: Daraxonrasib，Elironrasib，Zoldonrasib，Ivonescimab
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT07405476 / NCI-2026-00566

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

AI 简述这是一项II期试验，研究Zanidatamab用于HER2阳性结直肠癌术前治疗。

?

适用疾病: Colon Carcinoma；Colorectal Carcinoma；Rectal Carcinoma
干预: Zanidatamab，Resection，Patient Observation，Echocardiography Test
地点: United States
申办方: Emory University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07407465

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

AI 简述这是一项II期试验，研究T-DXd联合卡培他滨和贝伐珠单抗用于HER2阳性转移性结直肠癌。在法国、德国、意大利、西班牙等地开展。

?

适用疾病: Colorectal Cancer；Colorectal Adenocarcinoma；Rectal Adenocarcinoma
干预: Trastuzumab-Deruxtecan (T-DXd)，Capecitabine，Bevacizumab
地点: France，Germany，Italy，Spain
申办方: Gruppo Oncologico del Nord-Ovest

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07446322 / NCI-2026-02091

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

AI 简述这是一项II期试验，研究FOLFIRI和贝伐珠单抗联合Pelareorep用于RAS突变MSS转移性结直肠癌。

?

适用疾病: Ras-mutated Metastatic Colorectal Cancer；mCRC；MSS Metastatic Colorectal Cancer
干预: Bevacizumab，FOLFIRI，Pelareorep
地点: United States
申办方: Oncolytics Biotech

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07463599

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

AI 简述这是一项I/II期试验，研究Tegavivint用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Carcinoma (mCRC)；Colorectal Cancer (CRC)；Adenomatous Polyposis Coli (APC) Gene Mutation
干预: Tegavivint
地点: United States
申办方: HonorHealth Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07527858 / NCI-2026-03279

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

AI 简述这是一项II期试验，研究Denikitug单用或联合纳武利尤单抗/化疗用于晚期结直肠癌。

?

适用疾病: Advanced Microsatellite Stable Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Denikitug，Nivolumab，Bevacizumab，Trifluridine-Tipiracil
地点: United States，Australia
申办方: Gilead Sciences

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07529808

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

AI 简述这是一项I/II期试验，研究BHB810用于晚期胃癌和胃食管结合部腺癌。

?

适用疾病: Gastric Cancer；Gastric Adenocarcinoma；Gastric (Stomach) Cancer
干预: BHB810
地点: United States
申办方: BigHat Biosciences, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

AI 简述这是一项I/II期试验，研究BLU-924用于KRAS突变晚期实体瘤，在美国开展。

?

适用疾病: Advanced Solid Tumor；Non-Small Cell Lung Cancer；Colorectal Neoplasms
干预: BLU-924
地点: United States
申办方: Blueprint Medicines Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07659795

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

AI 简述这是一项II期试验，研究VS-7375用于KRAS G12D突变结直肠癌，在美国等地开展。

?

适用疾病: Colorectal Cancer
干预: VS-7375，cetuximab，panitumumab，Cetuximab + mFOLFOX6
地点: United States
申办方: Verastem, Inc.

即将招募 Phase 3

NCI NCT07271355 / NCI-2025-08527

Pressurized Intraperitoneal Aerosolized Chemotherapy with Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer with Peritoneal Metastases, The IMPACT Trial

AI 简述这是一项III期试验，在美国等地研究腹腔加压雾化化疗（丝裂霉素）用于不可切除阑尾或结直肠癌腹膜转移。

?

适用疾病: Stage IV Appendix Cancer；Stage IVC Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06446557

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

AI 简述这是一项III期试验，在法国开展，根据ctDNA变化调整转移性结直肠癌的治疗方案。

?

适用疾病: Metastatic Colon Cancer
干预: treatment adaptation guided by ctDNA variation，standard management
地点: France
申办方: University Hospital, Rouen

即将招募 Phase 3 诊断检测药物

ClinicalTrials.gov NCT07004413

Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

AI 简述这是一项III期试验，比较持续或间断西妥昔单抗联合FOLFIRI用于RAS/BRAF野生型转移性结直肠癌一线治疗，在德国开展。

?

适用疾病: Colorectal Cancer Metastatic
干预: FOLFIRI+cetuximab，Guardant360 ctDNA assay
地点: Germany
申办方: Charite University, Berlin, Germany

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06646445

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

AI 简述这是一项II期试验，研究帕博利珠单抗新辅助治疗联合观察等待策略用于dMMR/MSI-H局限期结肠癌。

?

适用疾病: Colon Cancer
干预: Pembrolizumab Injection [Keytruda]，Watch-and-wait approach，Surgery，Adjuvant chemotherapy
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06681038

Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)

AI 简述一项II期试验，全身抗肿瘤治疗加或不加腹腔加压气溶胶化疗用于结肠癌腹膜转移。

?

适用疾病: Peritoneal Metastases from Colorectal Cancer
干预: Standard Medical Therapy，PIPAC
地点: France
申办方: Institut Cancerologie de l'Ouest

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07071844

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

AI 简述这是一项II期试验，研究双周贝伐珠单抗联合曲氟尿苷替匹嘧啶用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: Trifluridine/tipiracil，Bevacizumab
地点: France
申办方: GERCOR - Multidisciplinary Oncology Cooperative Group

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07150403

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

AI 简述这是一项II期试验，在法国比较FOLFOX或FOLFIRI联合呋喹替尼与联合贝伐珠单抗用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Carcinoma (mCRC)
干预: Oxaliplatin intravenous，5 FU bolus，Folinic acid，5 FU continuous
地点: France
申办方: Federation Francophone de Cancerologie Digestive

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07178717

A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

AI 简述这是一项II期试验，研究Encorafenib联合Cetuximab再挑战用于BRAF V600E突变转移性结直肠癌，在西班牙开展。

?

适用疾病: Colo-rectal Cancer
干预: Rechalange with bevacizumab + encorafenib
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07277322

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

AI 简述这是一项I/II期试验，研究Dupilumab联合Toripalimab用于可切除肝转移的MSS结直肠癌，在美国开展。

?

适用疾病: Metastatic Colorectal Cancer；Liver Metastases
干预: Dupilumab，Toripalimab
地点: United States
申办方: Dan Feng

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07359456

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

AI 简述这是一项II期试验，研究依沃西单抗联合化疗对比贝伐珠单抗联合化疗用于无肝转移的转移性结直肠癌，在法国开展。

?

适用疾病: Metastatic Colorectal Cancer
干预: Ivonescimab，Bevacizumab，FOLFIRI Protocol
地点: France
申办方: UNICANCER

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07381764

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

AI 简述这是一项II期试验，在意大利开展，比较伊立替康+西妥昔单抗与曲氟尿苷替匹嘧啶+贝伐珠单抗用于分子筛选的转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)
干预: Erbitux (Cetuximab)，Bevacizumab，Irinotecan，Trifluridine/tipiracil
地点: Italy
申办方: Gruppo Oncologico Italia Meridionale

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07409844

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

AI 简述这是一项II期试验，研究新辅助免疫治疗用于I-III期dMMR结肠癌，在丹麦开展。

?

适用疾病: DMMR Colorectal Cancer；Colon Cancer Stage I；Colon Cancer Stage II/III
干预: 1 Cycle of Pembrolizumab，2 Cycles of Pembrolizumab，3 Cycles of Pembrolizumab，Additional Cycle of Pembrolizumab
地点: Denmark
申办方: Ismail Gögenur

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07550088

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

AI 简述这是一项2期试验，研究BAL/BOT/agenT-797用于pMMR结直肠癌肝转移。

?

适用疾病: Colorectal Cancer Metastatic
干预: Balstilimab (BAL)，Botensilimab (BOT)，agenT-797
地点: United States
申办方: Darren Sigal, MD

即将招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT07576725

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

AI 简述这是一项II期试验，在乌干达研究低剂量减少频率的Nivolumab用于不可切除或转移性癌症。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Nivolumab
地点: Uganda
申办方: Fred Hutchinson Cancer Center

即将招募 Phase 1, Phase 2 药物手术/操作

ClinicalTrials.gov NCT07594626

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

AI 简述这是一项I/II期试验，研究PRMT5抑制剂BMS-986504联合培美曲塞用于MTAP缺失的转移性实体瘤。

?

适用疾病: Metastatic Biliary Tract Carcinoma；Metastatic Colon Carcinoma；Metastatic Esophageal Carcinoma
干预: Biospecimen Collection，Computed Tomography，Pemetrexed，PRMT5 Inhibitor BMS-986504
地点: United States
申办方: Northwestern University

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT07612007 / NCI-2026-03702

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

AI 简述这是一项II期试验，研究HRX215用于结直肠癌肝转移患者。

?

适用疾病: Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm in the Liver；Resectable Colorectal Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Darizmetinib
地点: United States
申办方: Mayo Clinic

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

AI 简述这是一项I/II期试验，研究VMD-102用于肝细胞癌和其他实体瘤，在美国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Metastatic Uveal Melanoma；Renal Cell Carcinoma (RCC)
干预: VMD-102
地点: United States
申办方: VM Discovery, Inc.

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07662031

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Tovecimig联合FOLFIRI用于二线转移性结直肠癌。

?

适用疾病: Colorectal Cancer；Metastatic Colorectal Cancer
干预: Tovecimig，Irinotecan，Leucovorin，5-Fluorouracil (5-FU)
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07691489

A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan联合西妥昔单抗用于结直肠癌。

?

适用疾病: Colorectal Cancer；Adenocarcinoma of the Colon；Adenocarcinoma of the Rectum
干预: Fam-Trastuzumab Deruxtecan-Nxki
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07693751

A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic

AI 简述这是一项I/II期试验，首次研究SOT109用于不可切除或转移性结直肠癌，在美国等国开展。

?

适用疾病: Colorectal Cancer (Locally Advanced or Metastatic)
干预: SOT109
地点: United States，Moldova
申办方: SOTIO Biotech a.s.

正在招募 O

NCI NCT02172651 / NCI-2014-02032

Transcriptional and Immune Targets of Vitamin D in Patients with Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Cholecalciferol

AI 简述这是一项观察性试验，研究维生素D在术前接受胆钙化醇的I-III期结肠癌患者中的转录和免疫靶点。

?

适用疾病: Stage IIA Colon Cancer；Stage IIB Colon Cancer；Stage IIC Colon Cancer
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1

NCI NCT02433626 / NCI-2015-01738

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

AI 简述这是一项I期试验，研究COTI-2单药或联合治疗用于复发性晚期卵巢癌等恶性肿瘤。

?

适用疾病: Stage III Primary Peritoneal Cancer；Stage IIIA Primary Peritoneal Cancer；Stage IIIB Primary Peritoneal Cancer
干预: 未列出
地点: United States
申办方: Critical Outcome Technologies Inc.

正在招募 Phase 1

NCI NCT02600949 / NCI-2016-00015

Personalized Peptide Vaccine in Treating Patients with Advanced Pancreatic Cancer or Colorectal Cancer

AI 简述这是一项I期试验，研究个性化肽疫苗用于晚期胰腺癌或结直肠癌，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Pancreatic Cancer；Metastatic Pancreatic Ductal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT02675946 / NCI-2018-00241

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

AI 简述这是一项I期试验，研究CGX1321单用或联合Pembrolizumab或Encorafenib+Cetuximab用于晚期实体瘤和晚期胃肠道肿瘤。

?

适用疾病: Stage IIIA Esophageal Cancer；Stage IIIB Esophageal Cancer；Stage IIIC Esophageal Cancer
干预: 未列出
地点: United States
申办方: Curegenix Inc.

正在招募 Phase 1

NCI NCT04020276 / NCI-2019-04726

SBRT with MRI Guidance in Treating Patients with Liver Metastases

AI 简述这是一项I期试验，研究MRI引导SBRT用于肝转移性结直肠癌，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Stage IVA Colorectal (Colon or Rectal) Cancer；Stage IVB Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT04329494 / NCI-2020-01254

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients with Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

AI 简述这是一项I期试验，在美国开展，研究PIPAC用于卵巢癌、胃癌等的腹膜转移。

?

适用疾病: Stage IV Gastric (Stomach) Cancer；Stage IV Appendix Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04703101 / NCI-2020-06479

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

AI 简述这是一项I期试验，研究短程放疗联合化疗用于II-III期直肠癌。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04485013 / NCI-2020-07730

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

AI 简述这是一项I期试验，研究TTX-080用于晚期实体瘤，包括头颈鳞癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tizona Therapeutics, Inc

正在招募 Phase 1

NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: BioEclipse Therapeutics

正在招募 Phase 1

NCI NCT04677413 / NCI-2021-09429

Chemotherapy with Radiation for the Treatment of Rectal Cancer

AI 简述这是一项I期试验，研究化疗联合放疗用于局部晚期直肠癌。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT Southwestern/Simmons Cancer Center-Dallas

正在招募阶段未标明

NCI NCT05245786 / NCI-2021-14005

An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination with Standard of Care Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

AI 简述这是一项诊断性研究，评估64Cu标记M5A抗体联合标准放化疗用于局部晚期直肠癌。

?

适用疾病: Stage III Rectal Cancer；Locally Advanced Rectal Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT05433142 / NCI-2022-05582

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

AI 简述这是一项I期试验，研究XmAb819用于晚期透明细胞肾细胞癌。

?

适用疾病: Stage III Renal Cell Cancer；Stage IV Renal Cell Cancer；Refractory Colorectal Cancer
干预: 未列出
地点: United States
申办方: Xencor, Inc.

正在招募 Phase 1

NCI NCT05274048 / NCI-2022-05652

Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer

AI 简述这是一项I期试验，研究Neratinib联合Fam-Trastuzumab Deruxtecan用于晚期胃食管癌。

?

适用疾病: Unresectable Esophageal Carcinoma；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 1

NCI NCT05355701 / NCI-2022-06211

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

AI 简述这是一项I期试验，研究PF-07799933用于BRAF突变晚期实体瘤，在美国、加拿大、以色列等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Pfizer Inc

正在招募 Phase 1

NCI NCT05067283 / NCI-2022-06807

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

AI 简述这是一项1期试验，研究Calderasib用于KRAS突变晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1

NCI NCT05464030 / NCI-2022-07989

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

AI 简述这是一项I期试验，研究抗CEACAM5 ADC M9140用于晚期实体瘤。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Colorectal Cancer
干预: 未列出
地点: United States
申办方: EMD Serono Research & Development Institute, Inc.

正在招募 Phase 1

NCI NCT05329103 / NCI-2022-08461

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

AI 简述这是一项1期试验，研究PEEL-224用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Peel Therapeutics Inc

正在招募阶段未标明

NCI NCT04722341 / NCI-2022-09048

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

AI 简述这是一项关于限时进食对癌症影响的试验，涉及直肠癌和乳腺癌患者。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Stage IV Rectal Cancer
干预: 未列出
地点: United States
申办方: Cedars-Sinai Medical Center

正在招募 Phase 1

NCI NCT05719558 / NCI-2023-03815

A Study of ASP1002 in Adults for Treatment of Solid Tumors

AI 简述这是一项I期试验，在美国研究ASP1002用于多种晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma BV

正在招募阶段未标明

NCI NCT05265169 / NCI-2023-04304

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

AI 简述这是一项试验，研究消融治疗用于结直肠癌肝转移。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: Society of Interventional Oncology

正在招募阶段未标明

NCI NCT05947838 / NCI-2023-05381

Circulating Tumor DNA for Risk Determination and Treatment Selection in Patients with Carcinomatosis from Colorectal or Appendiceal Adenocarcinoma

AI 简述这是一项观察性研究，利用循环肿瘤DNA指导结直肠癌或阑尾腺癌腹膜转移患者的治疗。

?

适用疾病: Stage IV Appendix Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Resectable Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT05785754 / NCI-2023-05513

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DCSZ11单药及联合治疗用于晚期或转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DynamiCure Biotechnology

正在招募 Phase 1

NCI NCT06014502 / NCI-2023-06808

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

AI 简述这是一项I期试验，研究IMGS-001用于复发或难治性晚期实体瘤，包括头颈癌、鼻咽癌等。

?

适用疾病: Metastatic Head and Neck Cancer；Malignant Solid Tumor；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: ImmunoGenesis

正在招募 Phase 1

NCI NCT06004245 / NCI-2023-06836

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-133214单药及组合用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06026410 / NCI-2023-07364

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Darlifarnib联合Cabozantinib或Adagrasib用于晚期实体瘤。在美国、法国等地开展。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Kura Oncology, Inc.

正在招募 Phase 1

NCI NCT05989724 / NCI-2023-08586

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SON-DP用于标准治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Qurgen Inc.

正在招募 Phase 1

NCI NCT06131840 / NCI-2023-10543

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SGN-CEACAM5C用于晚期实体瘤，在美国、加拿大、中国、法国等地开展。

?

适用疾病: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT06240728 / NCI-2024-01335

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

AI 简述这是一项1期试验，研究NPX887用于表达B7-H7的实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06400472 / NCI-2024-05353

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

AI 简述这是一项I期试验，研究LY4170156联合其他药物用于晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06576037 / NCI-2024-07312

CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin

AI 简述这是一项I期试验，研究CBP-1019联合FOLFOX并用或不用其他药物治疗转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06462183 / NCI-2024-07823

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

AI 简述这是一项I期试验，研究RGT-61159用于复发/难治性腺样囊性癌或结直肠癌，在美国等地开展。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Refractory Colorectal Cancer
干预: 未列出
地点: United States
申办方: Rgenta Therapeutics Inc

正在招募 Phase 1

NCI NCT06475937 / NCI-2024-09195

A Study of DM001 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DM001用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06834126 / NCI-2024-10075

Papaverine in Combination with Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

AI 简述这是一项I期试验，研究罂粟碱联合放疗用于局部晚期直肠癌。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06720987 / NCI-2025-01560

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，在美国开展，研究KQB365单药或联合用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Rectal Cancer
干预: 未列出
地点: United States
申办方: Kumquat Biosciences Inc.

正在招募 Phase 1

NCI NCT06459869 / NCI-2025-02057

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

AI 简述这是一项I期试验，在美国研究NG-350A联合放化疗用于局部晚期直肠癌。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Locally Advanced Rectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Akamis Bio

正在招募阶段未标明

NCI NCT06896162 / NCI-2025-02181

A Precision Oncology Navigation and Expert Review Intervention for Improving Referral to Genome Informed Therapy among Patients with Stage IV Lung, Colorectal, Breast or Bladder Cancers, PROGRESS Trial

AI 简述这是一项试验，评估基因组指导治疗转诊改进用于IV期肺癌、结直肠癌、乳腺癌或膀胱癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06764771 / NCI-2025-02616

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

AI 简述这是一项I期试验，在美国研究BMS-986488单药或联合用于晚期恶性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1

NCI NCT06723236 / NCI-2025-03571

A Study of MGC028 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究MGC028用于晚期实体瘤。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: MacroGenics Inc

正在招募 Phase 1

NCI NCT06657144 / NCI-2025-04098

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究CHS-114（Tagmokitug）联合Toripalimab等用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Coherus Oncology, Inc.

正在招募 Phase 1

NCI NCT06804824 / NCI-2025-04592

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-159642用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募阶段未标明

NCI NCT05428735 / NCI-2025-05096

The DRAGON 2 Trial

AI 简述这是一项DRAGON 2试验，在未明确期别的条件下研究IV期结直肠癌伴肝转移。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm to the Liver
干预: 未列出
地点: United States
申办方: Academisch Ziekenhuis Maastricht

正在招募 Phase 1

NCI NCT07207707 / NCI-2025-07562

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究KQB548用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Kumquat Biosciences Inc.

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募 Phase 1

NCI NCT07213791 / NCI-2025-09175

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

AI 简述这是一项I期试验，在美国等地研究LY4337713用于FAP阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT07141706 / NCI-2025-09675

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究DB-1317用于晚期/转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1

NCI NCT07127874 / NCI-2026-00071

A Study of PHN-012 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PHN-012用于晚期实体瘤，在美国和西班牙开展。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Pheon Therapeutics

正在招募 Phase 1

NCI NCT07417488 / NCI-2026-00116

Cancer Vaccines (Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C) for the Treatment of Locally Advanced or Metastatic Colorectal and Small Bowel Cancer

AI 简述这是一项I期试验，在美国开展，研究癌症疫苗Ad5.F35-hGUCY2C-PADRE和Lm-GUCY2C用于结直肠癌和小肠癌。

?

适用疾病: Stage III Small Intestinal Adenocarcinoma；Stage IV Small Intestinal Adenocarcinoma；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Thomas Jefferson University Hospital

正在招募 Phase 1

NCI NCT07252479 / NCI-2026-00268

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

AI 简述这是一项I期试验，研究RAS抑制剂用于携带RAS突变的晚期或转移性实体瘤，于美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Adlai Nortye Biopharma Co., Ltd.

正在招募 Phase 1

NCI NCT07317505 / NCI-2026-01129

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究JMT108用于治疗晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Conjupro Bio-Pharmaceuticals Inc

正在招募 Phase 1

NCI NCT07300150 / NCI-2026-01752

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

AI 简述这是一项I期试验，研究PT0511联合西妥昔单抗用于KRAS突变或扩增的晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: PAQ Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06960395 / NCI-2026-02255

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究VIR-5525联合帕博利珠单抗用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Vir Biotechnology, Inc.

正在招募阶段未标明

NCI NCT07291180 / NCI-2026-03017

Mass-Based Response Testing to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Appendix and Colorectal Cancer in Patients with Peritoneal Metastasis

AI 简述这是一项试验，基于质量反应测试指导腹膜转移的阑尾癌和结直肠癌的个体化腹腔热灌注化疗。在美国开展。

?

适用疾病: Stage IV Appendix Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Yale University

正在招募 Phase 1

NCI NCT07544589 / NCI-2026-03246

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

AI 简述这是一项I期试验，在美国评估DISP-10用于晚期胃肠道癌症。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Dispatch Biotherapeutics

正在招募 Phase 1

NCI NCT07594067 / NCI-2026-04690

Genetically Engineered Cells (TCR1188-ABC) for the Treatment of Metastatic Pancreatic Cancer, Cholangiocarcinoma, Colorectal Cancer, or Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，在美国开展，研究TCR1188-ABC细胞用于KRAS突变胆管癌、结直肠癌、非小细胞肺癌和胰腺癌。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Hilar Cholangiocarcinoma；Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT01479608

Liver Transplantation and Colorectal Cancer

AI 简述这是一项试验，研究肝移植用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer；Liver Metastasis
干预: Liver transplantation and liver resection
地点: Norway
申办方: Oslo University Hospital

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT03488953

Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases

AI 简述这是一项试验，研究活体肝移植联合两阶段肝切除术用于不可切除的结直肠癌肝转移。

?

适用疾病: Colorectal Cancer Metastatic；Liver Metastases
干预: Living donor liver transplantation with two-staged hepatectomy.
地点: Germany
申办方: Jena University Hospital

正在招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT03494946

Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer

AI 简述这是一项试验，比较肝移植与化疗用于结直肠癌肝转移。在挪威开展。

?

适用疾病: Liver Metastases；Colorectal Cancer
干预: Liver transplantation，Chemotherapy
地点: Norway
申办方: Oslo University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT03692429

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

AI 简述这是一项I期试验，研究CYAD-101联合化疗用于不可切除转移性结直肠癌。

?

适用疾病: Unresectable Metastatic Colorectal Cancer
干预: CYAD-101，FOLFOX，FOLFIRI
地点: United States，Belgium
申办方: Celyad Oncology SA

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT03715933 / NCI-2018-03556

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

AI 简述一项I期试验，研究INBRX-109联合伊立替康等用于晚期实体瘤包括肉瘤，在美国、法国等地开展。

?

适用疾病: Ewing Sarcoma；Colorectal Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: INBRX-109，Irinotecan，Temozolomide，carboplatin
地点: United States，France，Italy，Netherlands 等 2 个
申办方: Inhibrx Biosciences, Inc

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

AI 简述这是一项I期试验，研究CAdVEC用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04221893 / NCI-2019-08355

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

AI 简述这是一项试验，研究放射治疗用于转移性胃肠癌，包括食管癌、胃癌等。

?

适用疾病: Stage IV Esophageal Adenocarcinoma；Stage IV Esophageal Squamous Cell Carcinoma；Stage IV Gastric Cancer
干预: Radiation Therapy (RT)
地点: United States
申办方: University of California, San Francisco

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04222413 / NCI-2020-00306

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究Metarrestin（ML-246）用于转移性实体瘤，包括胰腺癌和乳腺癌。

?

适用疾病: Advanced Solid Tumors；Metastatic Pancreatic Cancer；Pediatric Solid Tumor
干预: Metarrestin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04511039 / NCI-2020-05678

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

AI 简述这是一项I期试验，研究Trifluridine/Tipiracil联合Talazoparib用于局部晚期或转移性结直肠癌或胃食管癌。

?

适用疾病: Advanced Malignant Solid Neoplasm；Clinical Stage III Gastroesophageal Junction Adenocarcinoma；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
干预: Trifluridine and Tipiracil Hydrochloride，Talazoparib Tosylate
地点: United States
申办方: Roswell Park Cancer Institute

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04678583

Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer

AI 简述这是一项试验，研究肝脏转移灶切除术用于RAS突变结直肠癌肝转移患者。在德国开展。

?

适用疾病: Colorectal Liver Metastasis
干预: Resection of colorectal liver metastases
地点: Germany
申办方: Technische Universität Dresden

正在招募 Phase 1 诊断检测药物

ClinicalTrials.gov / NCI NCT04929223 / NCI-2021-08561

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

AI 简述这是一项I期试验，研究靶向治疗用于转移性结直肠癌亚组，在多个国家开展。

?

适用疾病: Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Carcinoma
干预: Inavolisib，Bevacizumab，Cetuximab，Atezolizumab
地点: United States，Australia，Canada，Denmark 等 7 个
申办方: Hoffmann-La Roche

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04991948

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究CYAD-101联合FOLFOX预处理后Pembrolizumab用于不可切除转移性结直肠癌。

?

适用疾病: Unresectable Metastatic Colorectal Cancer
干预: CYAD-101，FOLFOX，Pembrolizumab
地点: United States，Belgium
申办方: Celyad Oncology SA

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04999761

AB122 Platform Study

AI 简述这是一项I期试验，研究AB122联合TAS-116、TAS-120、TAS-115用于晚期或转移性实体瘤，在日本开展。

?

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05176483 / NCI-2022-05617

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

AI 简述这是一项I期试验，研究Zanzalintinib联合免疫药物用于实体瘤，在多国开展。

?

适用疾病: Renal Cell Carcinoma (RCC)；Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Urothelial Carcinoma (UC)
干预: Zanzalintinib，Nivolumab，Ipilimumab，Nivolumab + Relatlimab
地点: United States，Australia，Austria，Belgium 等 9 个
申办方: Exelixis

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05185245

Liver Transplantation for Non-Resectable Colorectal Liver Metastasis

AI 简述这是一项肝移植试验，用于不可切除的结直肠癌肝转移。在意大利开展。

?

适用疾病: Liver Metastasis Colon Cancer；Colorectal Cancer
干预: Liver Transplantation
地点: Italy
申办方: IRCCS Azienda Ospedaliero-Universitaria di Bologna

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT05186116

LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis

AI 简述这是一项活体肝移植试验，用于不可切除的结直肠癌肝转移。在意大利开展。

?

适用疾病: Colon Adenocarcinoma；Liver Metastasis Colon Cancer
干预: Living donor liver transplant, Split liver transplant, RAPID, DDLT
地点: Italy
申办方: Azienda Ospedaliero-Universitaria di Modena

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05195710 / NCI-2021-13239

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

AI 简述这是一项I期试验，研究术前钇-90放射栓塞用于结直肠癌肝转移。在美国开展。

?

适用疾病: Metastases；Stage IV Colorectal (Colon or Rectal) Cancer；Colorectal (Colon or Rectal) Cancer
干预: Yttrium-90 (Y-90) resin microspheres
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05283330 / NCI-2022-07733

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

AI 简述这是一项I期试验，研究²¹²Pb-DOTAM-GRPR1用于GRPR阳性的复发或转移性实体瘤。

?

适用疾病: Cervical Cancer；Breast Cancer；Colon Cancer
干预: ²¹²Pb-DOTAM-GRPR1
地点: United States
申办方: Orano Med Theranostics, SAS

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05427487

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

AI 简述这是一项1期试验，研究瘤内注射IVX037用于晚期或转移性实体瘤。

?

适用疾病: Colorectal Cancer；Gastric Cancer；Ovarian Cancer
干预: IVX037，Sintilimab
地点: Australia
申办方: ImmVirx Pty Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05581004

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究Enzelkitug单药或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；NSCLC；HNSCC
干预: Enzelkitug，Atezolizumab，Pembrolizumab
地点: United States，Australia，Belgium，Canada 等 6 个
申办方: Genentech, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05611034

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

AI 简述这是一项I期试验，研究体内肺灌注奥沙利铂用于结直肠癌肺转移，在加拿大开展。

?

适用疾病: Lung Metastases；Colorectal Cancer Metastatic；Colorectal Cancer
干预: Oxaliplatin
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05746897

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究NM1F（抗PVRIG）用于晚期实体瘤，包括卵巢癌、黑色素瘤等，在美国开展。

?

适用疾病: Ovarian Cancer；Melanoma；Triple Negative Breast Cancer
干预: NM1F Injection，Pembrolizumab injection
地点: United States
申办方: Hefei TG ImmunoPharma Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05759923

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

AI 简述这是一项1期试验，研究OATD-02用于晚期及/或转移性实体瘤。

?

适用疾病: Advanced Ovarian Carcinoma；Advanced Renal Cell Carcinoma；Advanced Pancreatic Carcinoma
干预: OATD-02
地点: Poland
申办方: Molecure S.A.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05803382 / NCI-2023-02652

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

AI 简述这是一项I期试验，研究ZEN003694联合卡培他滨用于转移性或不可切除的实体瘤。

?

适用疾病: Metastatic Colorectal Carcinoma；Metastatic Malignant Solid Neoplasm；Stage IV Colorectal Cancer AJCC v8
干预: BET Bromodomain Inhibitor ZEN-3694，Biopsy Procedure，Biospecimen Collection，Capecitabine
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05848739 / NCI-2023-08892

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

AI 简述这是一项1-2期试验，研究ST316用于晚期不可切除和转移性实体瘤。

?

适用疾病: Colon Cancer；Metastatic Colon Cancer；Advanced Malignant Solid Tumor
干预: ST316，FOLFIRI regimen & bevacizumab，Fruquintinib，Lonsurf & bevacizumab
地点: United States
申办方: Sapience Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05856981 / NCI-2023-06437

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

AI 简述这是一项1期试验，研究ADU-1805用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Metastatic Solid Tumor；Refractory Cancer
干预: ADU-1805，Pembrolizumab
地点: United States，Belgium，Spain
申办方: Sairopa B.V.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05877599 / NCI-2023-04428

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AI 简述这是一项I期试验，研究TP53 R175H靶向T细胞用于HLA-A*02:01阳性晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Colorectal Carcinoma
干预: Autologous, engineered T Cells targeting TP53 R175H
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05985954 / NCI-2023-06254

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

AI 简述这是一项I期试验，研究Ulixertinib联合Cetuximab或联合Encorafenib用于结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Cetuximab，Ulixertinib，Encorafenib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06012734

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

AI 简述这是一项I期试验，研究LB-100联合Atezolizumab用于转移性微卫星稳定结直肠癌。

?

适用疾病: Metastatic Microsatellite-stable Colorectal Cancer
干预: LB-100，Atezolizumab
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RMC-9805用于KRAS G12D突变实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-9805，RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募阶段未标明药物

ClinicalTrials.gov NCT06126419

Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration

AI 简述这是一项研究高剂量胰岛素疗法用于肝功能障碍和结肠癌肝转移的试验，在加拿大开展。

?

适用疾病: Liver Dysfunction；Liver Metastasis Colon Cancer；Liver Regeneration
干预: High-Dose Insulin Therapy
地点: Canada
申办方: McGill University Health Centre/Research Institute of the McGill University Health Centre

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06200831

Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases

AI 简述这是一项试验，比较同期切除与分期切除用于结直肠癌同时性肝转移。

?

适用疾病: Colorectal Cancer；Colorectal Neoplasms Malignant；Liver Metastasis Colon Cancer
干预: Staged resection，Simultaneous resection
地点: Norway
申办方: Oslo University Hospital

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06218914 / NCI-2024-01226

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究靶向KRAS G12D的T细胞疗法用于不可切除晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Colorectal Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: NT-112: Autologous, engineered T Cells targeting KRAS G12D，AZD0240: Autologous, engineered T Cells targeting KRAS G12D
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

AI 简述这是一项I/Ib期试验，研究IAM1363用于HER2相关肿瘤，在美国、法国、爱尔兰、意大利等地开展。

?

适用疾病: HER2 Mutation-Related Tumors；HER2；HER2-positive Breast Cancer
干预: IAM1363
地点: United States，France，Ireland，Italy 等 4 个
申办方: Iambic Therapeutics, Inc

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06269978 / NCI-2023-10497

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer

AI 简述这是一项I期试验，研究腹腔内奥沙利铂和氟尿嘧啶用于结直肠癌腹膜转移。

?

适用疾病: Metastatic Colorectal Carcinoma；Metastatic Malignant Neoplasm in the Peritoneum；Stage IV Colorectal Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Diagnostic Laparoscopy
地点: United States
申办方: Arjun Mittra

正在招募 Phase 1 生物制剂Dietary_Supplement其他

ClinicalTrials.gov / NCI NCT06336902 / NCI-2024-01368

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究Botensilimab联合Balstilimab和模拟禁食饮食加维生素C用于KRAS突变转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Stage IV Colorectal Cancer AJCC v8；Stage IV Colorectal (Colon or Rectal) Cancer
干预: Balstilimab，Biospecimen Collection，Botensilimab，Computed Tomography
地点: United States
申办方: University of Southern California

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06411691 / NCI-2025-01263

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

AI 简述这是一项I期试验，研究KRAS疫苗联合Balstilimab和Botensilimab用于IV期结直肠癌和胰腺导管癌，在美国开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: KRAS Vaccine with Poly-ICLC adjuvant，Balstilimab，Botensilimab
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AGX101用于晚期实体瘤。

?

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06462963

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

AI 简述这是一项在比利时、意大利、荷兰、瑞士等地开展的试验，比较单次与多次SBRT用于寡转移性乳腺癌、前列腺癌、非小细胞肺癌、结直肠癌。

?

适用疾病: Breast Cancer；Prostate Cancer；NSCLC
干预: single-fraction SBRT，multiple-fraction SBRT
地点: Belgium，Italy，Netherlands，Switzerland
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06562192 / NCI-2024-08464

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

AI 简述这是一项I期试验，研究[177Lu]Lu-NNS309用于胰腺癌、肺癌、乳腺癌和结直肠癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: [68Ga]Ga-NNS309，[177Lu]Lu-NNS309
地点: United States，Belgium，Canada，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06625775 / NCI-2024-09407

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究BBO-10203用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Metastatic Breast Cancer；Advanced Breast Cancer
干预: BBO-10203，Trastuzumab，Fulvestrant，Ribociclib
地点: United States，Australia，Brazil，France 等 1 个
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06654037 / NCI-2024-08691

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

AI 简述这是一项I期试验，研究Abemaciclib联合氟尿嘧啶用于转移性难治性结直肠癌，在美国开展。

?

适用疾病: Metastatic Microsatellite Stable Colorectal Carcinoma；Refractory Microsatellite Stable Colorectal Carcinoma；Stage IV Colorectal Cancer AJCC v8
干预: Abemaciclib，Biopsy Procedure，Biospecimen Collection，Fluorouracil
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06663319 / NCI-2025-00139

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

AI 简述这是一项I期试验，研究JNJ-89402638用于转移性结直肠癌和胃癌。

?

适用疾病: Colorectal Neoplasms；Gastrointestinal Neoplasms；Stage III Colorectal (Colon or Rectal) Cancer
干预: JNJ-89402638，Bevacizumab，FOLFOX，FOLFIRI
地点: United States，South Korea，Spain
申办方: Janssen Research & Development, LLC

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06663839

A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer

AI 简述这是一项I期试验，研究NILK-2301用于局部晚期或转移性低肿瘤负荷结直肠癌。

?

适用疾病: Colorectal Cancer Metastatic
干预: Biological NILK-2301
地点: Spain
申办方: Light Chain Bioscience - Novimmune SA

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06696768 / NCI-2024-09416

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

AI 简述这是一项1期试验，研究Emavusertib联合FOLFOX及贝伐珠单抗用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Stage III Colorectal Cancer AJCC v8；Stage IV Colorectal Cancer AJCC v8
干预: Bevacizumab，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06756035 / NCI-2025-04725

CT-95 in Advanced Cancers Associated With Mesothelin Expression

AI 简述这是一项I期试验，研究CT-95用于间皮素表达的晚期实体瘤，包括卵巢癌、间皮瘤和胰腺癌。

?

适用疾病: Mesothelin-Expressing Tumors；Epithelial Ovarian Cancer；Malignant Pleural Mesothelioma, Advanced
干预: CT-95
地点: United States
申办方: Context Therapeutics Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

AI 简述这是一项I期试验，研究CLSP-1025用于p53 R175H突变实体瘤。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 Phase 1 联合产品药物其他

ClinicalTrials.gov / NCI NCT06789172 / NCI-2025-08170

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

AI 简述这是一项I期试验，研究OKN4395联合帕博利珠单抗用于实体瘤，包括肉瘤、头颈癌、非小细胞肺癌。

?

适用疾病: Solid Tumours；Sarcoma；HNSCC
干预: OKN4395，Pembrolizumab，Fasting，Fed
地点: United States，Australia，United Kingdom
申办方: Epkin

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06835569

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

AI 简述这是一项I期试验，研究ALTA3263用于KRAS突变的晚期实体瘤，包括胰腺癌、非小细胞肺癌、结直肠癌等，在美国开展。

?

适用疾病: Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC (Non-small Cell Lung Cancer)
干预: ALTA3263，cetuximab，mFOLFOX6，Pembrolizumab
地点: United States
申办方: Alterome Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06853496

Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究RK-582用于不可切除转移性结直肠癌。

?

适用疾病: Unresectable Colorectal Neoplasm Metastasis
干预: RK-582
地点: Japan
申办方: Eiji Shinozaki

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06867822 / NCI-2025-07479

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究ProAgio联合FOLFIRI和贝伐珠单抗用于晚期转移性结直肠癌。

?

适用疾病: Advanced Colorectal Cancer；Metastatic Colorectal Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: ProAgio，FOLFIRI，Bevacizumab
地点: United States
申办方: University of Alabama at Birmingham

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06882746 / NCI-2025-03676

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

AI 简述这是一项I期试验，在美国研究BI 765049用于晚期结直肠癌、胃癌或胰腺癌。

?

适用疾病: Colorectal Carcinoma；Gastric Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: BI 765049
地点: United States
申办方: Boehringer Ingelheim

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06917079 / NCI-2025-02810

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

AI 简述这是一项I期试验，研究BBO-11818用于KRAS突变实体瘤，在美国和澳大利亚开展。

?

适用疾病: Non-Small Cell Lung Cancer；NSCLC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: BBO-11818，Pembrolizumab，Platinum chemotherapy (cisplatin or carboplatin)，Pemetrexed
地点: United States，Australia
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06974110

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究MOMA-341用于晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Endometrial Cancer
干预: MOMA-341，Irinotecan，Immunotherapy
地点: United States，Australia
申办方: MOMA Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[225Ac]Ac-AKY-1189用于多种晚期实体瘤，在美国开展。

?

适用疾病: Urothelial Carcinoma Bladder；Triple Negative Breast Cancer (TNBC)；Hormone Receptor Positive Breast Adenocarcinoma
干预: [225Ac]Ac-AKY-1189 (therapeutic)，[64Cu]Cu-AKY-1189 (imaging)
地点: United States
申办方: Aktis Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07085091 / NCI-2025-05711

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，在美国开展，首次研究ALX2004用于晚期或转移性实体瘤。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；HNSCC；CRC (Colorectal Cancer)
干预: ALX2004
地点: United States
申办方: ALX Oncology Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07094204 / NCI-2025-06344

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

AI 简述这是一项I期试验，研究ASP5834用于实体瘤，在美国、法国等地开展。

?

适用疾病: Solid Tumor；Non-Small-Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma
干预: ASP5834，panitumumab
地点: United States，France，Japan，Spain
申办方: Astellas Pharma Inc

正在招募 EARLY / Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT07128355 / NCI-2026-04004

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

AI 简述这是一项早期I期试验，研究立体定向放疗联合Botensilimab和Balstilimab用于非MSI-H/pMMR结直肠癌肝转移，在美国开展。

?

适用疾病: Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma
干预: Stereotactic Body Radiation Therapy (SBRT)，Botensilimab，Balstilimab
地点: United States
申办方: Massachusetts General Hospital

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07172282

INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases

AI 简述这是一项早期I期试验，研究Nelitolimod用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer Metastatic
干预: Nelitolimod
地点: United States
申办方: Northwell Health

正在招募 EARLY / Phase 1 联合产品

ClinicalTrials.gov NCT07193862

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

AI 简述这是一项早期I期试验，研究植入式微装置评估结直肠癌肝转移患者药物反应。

?

适用疾病: Colorectal Cancer Metastatic
干预: Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
地点: United States
申办方: Northwell Health

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT07194616

Rectal Cancer CTC Trial

AI 简述这是一项观察性试验，研究循环肿瘤细胞在直肠癌患者中的意义。

?

适用疾病: Rectal Cancer Patients
干预: Primary Surgery，Neoadjuvant radiochemotherapy and surgery
地点: Czechia
申办方: University Hospital Ostrava

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07227168 / NCI-2026-01753

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

AI 简述这是一项I期试验，研究STRO-004联合Pembrolizumab用于难治性/复发性转移性实体瘤，在美国开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DFC413用于多种实体瘤，在加拿大、丹麦、法国、德国等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-Small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: 68Ga-NNS309，177Lu-DFC413
地点: Canada，Denmark，France，Germany 等 2 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07318805 / NCI-2026-00338

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PF-08032562用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Advanced Breast Cancer；Metastatic Breast Cancer (HR+/ HER2-)；Colorectal Cancer
干预: PF-08032562，Fulvestrant，Cetuximab，Fluorouracil
地点: United States
申办方: Pfizer

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT07321106 / NCI-2026-01990

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

AI 简述这是一项I期试验，研究CBI-1214用于晚期或转移性MSS/MSI-L结直肠癌，在美国开展。

?

适用疾病: Colorectal Cancer；Colorectal Cancer (CRC)；Colorectal (Colon or Rectal) Cancer
干预: CBI-1214
地点: United States
申办方: Cartography Biosciences

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov NCT07328087

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

AI 简述这是一项早期I期试验，研究COLONYVAQ™个体化新抗原疫苗联合化疗用于MSS III期结直肠癌，在希腊开展。

?

适用疾病: Colorectal Cancer Metastatic；Colorectal Cancer Stage III；Colorectal Cancer Stage IV
干预: Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
地点: Greece
申办方: Biogenea Pharmaceuticals Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，研究AVA6103用于局部晚期或转移性实体瘤。

?

适用疾病: Vulvar Adenocarcinoma；PDAC - Pancreatic Ductal Adenocarcinoma；Gastric Adenocarcinoma
干预: AVA6103
地点: United States
申办方: Avacta Life Sciences Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07458347 / NCI-2026-03309

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

AI 简述这是一项I期试验，研究KST-6051用于KRAS突变晚期实体瘤，包括非小细胞肺癌、胰腺癌、结直肠癌等。在美国开展。

?

适用疾病: KRAS-mutant Non-small Cell Lung Cancer (NSCLC)；KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)；KRAS-mutant Colorectal Cancer (CRC)
干预: KST-6051
地点: United States
申办方: Kestrel Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07500298 / NCI-2026-02086

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究SAR445877联合FOLFOX6和贝伐珠单抗用于一线转移性结直肠癌。

?

适用疾病: Phase 1；SAR445877；FOlfox6
干预: SAR445877，FOLFOX6，Bevacizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07535112 / NCI-2026-03933

A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

AI 简述这是一项I期试验，研究BAY 3771249用于KRAS G12D突变晚期结直肠癌。

?

适用疾病: Advanced/Metastatic Colorectal Adenocarcinoma；Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: BAY 3771249，Cetuximab
地点: United States，Australia，Belgium，Denmark 等 6 个
申办方: Bayer

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07540572

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE574联合Fulvestrant用于多种晚期实体瘤，在美国开展。

?

适用疾病: ER+, HER 2- Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Castration-resistant Prostate Cancer (CRPC)
干预: IDE574，Fulvestrant injection
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07543744

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

AI 简述这是一项I期试验，比较RPH-030与Vectibix®联合FOLFIRI方案用于RAS野生型转移性结直肠癌一线治疗。

?

适用疾病: Metastatic Colorectal Cancer
干预: RPH-030，Vectibix®，Irinotecan，Calcium Folinate
地点: Russia
申办方: R-Pharm

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03026140

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

AI 简述这是一项II期试验，研究Nivolumab联合Ipilimumab等用于早期结肠癌的新辅助治疗。在荷兰开展。

?

适用疾病: Colon Carcinoma
干预: Nivolumab，Ipilimumab，Celecoxib 200mg，BMS-986253
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04959604

Lymph Node Mapping Via Flourescent Dye in Colon Cancer

AI 简述这是一项试验，研究荧光染料ICG用于结肠癌淋巴结定位，在德国开展。

?

适用疾病: Colon Carcinoma；Lymph Node Metastases
干预: ICG-marking endoscopically
地点: Germany
申办方: Universitätsklinikum Hamburg-Eppendorf

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

AI 简述这是一项II期试验，研究Dostarlimab用于dMMR/MSI的局部晚期或转移性癌症。

?

适用疾病: Pancreatic Adenocarcinoma；Ampulla of Vater Carcinoma；Adrenocortical Carcinoma
干预: Dostarlimab，Chemotherapy
地点: France
申办方: UNICANCER

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06567782

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

AI 简述这是一项II期试验，研究Dostarlimab联合CAPEOX新辅助治疗既往未经治疗的T4N0或III期错配修复完整/微卫星稳定结肠癌，在比利时、意大利、日本、西班牙等地开展。

?

适用疾病: Neoplasms, Colon
干预: Dostarlimab，CAPEOX
地点: Belgium，Italy，Japan，Spain 等 2 个
申办方: GlaxoSmithKline

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06833866

Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究5-氟尿嘧啶联合Hydroxytyrosol用于晚期或转移性结直肠癌。

?

适用疾病: Advanced or Metastatic CRC
干预: Hydroxytyrosol
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06978400

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究达拉非尼联合西妥昔单抗或帕尼单抗及FOLFOX用于转移性结直肠癌的一线治疗，在俄罗斯开展。

?

适用疾病: Neoplasms
干预: mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy
地点: Russia
申办方: Blokhin's Russian Cancer Research Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07204574

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

AI 简述这是一项I/II期试验，研究HCB101联合西妥昔单抗、贝伐珠单抗及FOLFOX/FOLFIRI用于晚期或转移性结直肠癌，在台湾开展。

?

适用疾病: CRC
干预: HCB101，Bevacizumab，Cetuximab (Erbitux)，FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
地点: Taiwan
申办方: Chang Gung Memorial Hospital

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06343116

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer

AI 简述这是一项III期试验，研究尼妥珠单抗联合曲氟尿苷/替吡嘧啶用于难治性转移性结直肠癌。

?

适用疾病: Refractory Metastatic Colorectal Cancer
干预: Nimotuzumab injection，Placebo，Trifluridine/tipiracil
地点: 未列出
申办方: Biotech Pharmaceutical Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06832917

Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)

AI 简述这是一项III期试验，研究短程放疗联合Cadonilimab和MFOLFOX6新辅助治疗局部晚期直肠癌。

?

适用疾病: Rectal Cancer
干预: AK104 plus，Chemo only
地点: 未列出
申办方: Wan He

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07025239

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

AI 简述这是一项III期试验，比较QL1706联合贝伐珠单抗和XELOX与安慰剂联合贝伐珠单抗和XELOX用于一线治疗不可切除转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: QL1706，Bevacizumab，Oxaliplatin，Capecitabine
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07284394

Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease

AI 简述这是一项III期试验，研究肝动脉灌注化疗对比静脉化疗用于结直肠癌肝转移术后高复发风险患者。

?

适用疾病: Colorectal Adenocarcinoma Metastatic in the Liver；Colorectal Cancer
干预: Arterial catheter infusion chemotherapy，IV Chemotherapy (Regimen 1)
地点: 未列出
申办方: UNICANCER

即将招募 Phase 2, Phase 3 药物手术/操作

ClinicalTrials.gov NCT07321847

Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases

AI 简述这是一项II/III期试验，研究IP-001注射联合热消融用于结直肠癌肝转移。

?

适用疾病: Colorectal Cancer (CRC)；Colon Cancer Liver Metastases；Rectal Cancer
干预: 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water，1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water.，Microwave (thermal) tumor ablation
地点: 未列出
申办方: Immunophotonics, Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT03919292 / NCI-2019-02675

Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers

AI 简述这是一项I/II期试验，研究Neratinib和Divalproex Sodium用于晚期实体瘤或RAS突变癌症，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colon Cancer；Stage IV Colon Cancer
干预: 未列出
地点: United States
申办方: VCU Massey Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT03970382 / NCI-2019-03772

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究基因编辑的TCR T细胞联合或不联合抗PD-1用于多种实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: PACT Pharma, Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT04017650 / NCI-2019-04169

Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

AI 简述这是一项I/II期试验，研究Encorafenib、Cetuximab和Nivolumab用于BRAF V600E突变结直肠癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Microsatellite Stable Colorectal Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT04714983 / NCI-2021-00608

DNX-2440 for Resectable Colorectal Liver Metastasis

AI 简述这是一项I期试验，研究DNX-2440用于可切除的结直肠癌肝转移，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DNAtrix, Inc.

暂时不招募 Phase 1

NCI NCT05159050 / NCI-2022-03835

Paclitaxel-Loaded Tumor Penetrating Microparticles for the Treatment of Peritoneal Carcinomatosis

AI 简述这是一项I期试验，研究紫杉醇负载肿瘤穿透微粒用于腹膜癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Gastric Carcinoma；Metastatic Ovarian Carcinoma
干预: 未列出
地点: United States
申办方: University of Iowa/Holden Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT05400122 / NCI-2022-07858

Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers

AI 简述这是一项I期试验，研究通用供者NK细胞联合Aldesleukin和Vactosertib用于局部晚期或转移性结直肠癌、胃癌、食管癌及血液肿瘤。

?

适用疾病: Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT05200442 / NCI-2022-10763

Avutometinib and Cetuximab for the Treatment of Metastatic KRAS Mutated Colorectal Cancer

AI 简述这是一项I/II期试验，研究Avutometinib联合西妥昔单抗用于KRAS突变转移性结直肠癌。在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma；Advanced Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Chicago Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT06102902 / NCI-2023-08787

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab plus Encorafenib, for Colorectal Cancer

AI 简述这是一项I期试验，研究ZEN003694联合西妥昔单抗和encorafenib用于IV期结直肠癌，在美国开展。

?

适用疾病: Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma；Refractory Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: University of Texas MD Anderson Cancer Center LAO

暂时不招募 Phase 2

NCI NCT07011550 / NCI-2025-04161

BMS-986340, Nivolumab, Trifluridine/Tipiracil and Bevacizumab for the Treatment of Refractory, Microsatellite-Stable, Locally Advanced, Unresectable or Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究BMS-986340联合Nivolumab、Trifluridine/Tipiracil和Bevacizumab用于微卫星稳定型结直肠癌，在美国开展。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Colorectal Adenocarcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募 Phase 1

NCI NCT07487168 / NCI-2026-02444

Pressurized Intraperitoneal Aerosol Chemotherapy with Mitomycin C for the Treatment of Peritoneal Carcinomatosis from Gastrointestinal Cancers

AI 简述这是一项I期试验，研究腹腔内加压气雾化疗丝裂霉素C用于胃肠道癌腹膜转移，在美国开展。

?

适用疾病: Metastatic Colorectal Adenocarcinoma；Metastatic Appendix Adenocarcinoma；Appendix Goblet Cell Adenocarcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

即将招募阶段未标明手术/操作放疗

ClinicalTrials.gov NCT05808790

Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy

AI 简述这是一项观察性研究，比较肺转移灶切除与立体定向放疗用于结直肠癌肺转移。

?

适用疾病: Lung Metastases；Colorectal Cancer Metastatic
干预: Minimally invasive pulmonary metastasectomy，Stereotactic ablative radiotherapy
地点: Netherlands
申办方: Amsterdam UMC, location VUmc

即将招募阶段未标明放疗

ClinicalTrials.gov NCT06053996

Hepatopulmonary Radio-sterilization With Immunotherapy

AI 简述这是一项在以色列开展的试验，研究肝肺放射灭菌联合免疫治疗用于结肠癌肝转移。

?

适用疾病: Colon Cancer；Liver Metastasis Colon Cancer；Rectal Cancer
干预: Hepatopulmonary radio-sterilization
地点: Israel
申办方: Sheba Medical Center

即将招募 EARLY / Phase 1 药物其他

ClinicalTrials.gov / NCI NCT07318389 / NCI-2025-09705

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

AI 简述这是一项早期I期试验，研究动态肿瘤耐药机制用于转移性结直肠癌，在美国开展。

?

适用疾病: Dynamic Tumor Resistance；Metastatic Colorectal Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: SOC (Standard of care)，Bevacizumab，Cetuximab，Panitumumab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07363408 / NCI-2025-09719

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究Ivonescimab和ADG126单独或联合化疗用于微卫星稳定晚期/转移性结直肠癌，在美国开展。

?

适用疾病: Advanced Microsatellite Stable Colorectal Carcinoma；Metastatic Microsatellite Stable Colorectal Carcinoma；Stage III Colorectal Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Fluorouracil，Irinotecan
地点: United States
申办方: City of Hope Medical Center

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07416552

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

AI 简述这是一项I期试验，在美国开展，研究CEA-PRIT 2.0用于转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer
干预: SPLIT Abs，203Pb-DOTAM，212Pb-DOTAM
地点: United States
申办方: Hoffmann-La Roche

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07566897

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究L19IL2联合Ruxolitinib用于晚期实体瘤。

?

适用疾病: Renal Carcinoma Metastatic；Pancreatic Adenocarcinoma Metastatic；Pancreatic Adenocarcinoma
干预: L19IL2，Ruxolitinib
地点: Italy
申办方: Philogen S.p.A.

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07587827

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

AI 简述这是一项I期试验，在法国开展，研究个性化疫苗ODI-2001（包含DNA新抗原疫苗、MVA病毒载体和Ipilimumab）用于转移性或局部晚期结直肠癌或胰腺癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)；Locally Advanced Colorectal Cancer；Metastatic Pancreatic Cancer
干预: Personalized cancer vaccine including : DNA neoantigen vaccine, MVA viral vector and Ipilimumab (anti-CTLA4)
地点: France
申办方: Centre Georges Francois Leclerc

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07627191

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

AI 简述这是一项早期I期试验，研究GLP-1受体激动剂（司美格鲁肽）联合标准治疗用于一线转移性胰腺癌、结直肠癌或肝细胞癌。

?

适用疾病: Pancreatic Cancer；Colorectal Cancer；Hepatocellular Carcinoma
干预: GLP1-RA (semaglutide)
地点: United States
申办方: University of Arizona

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07658196

TLR9 Immunotherapy for Peritoneal Carcinomatosis

AI 简述这是一项I期试验，研究ACM-CpG用于腹膜癌病，在美国开展。

?

适用疾病: Malignant Ascites；Colorectal Adenocarcinoma；Peritoneal (Metastatic) Cancer
干预: ACM-CpG
地点: United States
申办方: Brown University

即将招募阶段未标明药物

ClinicalTrials.gov NCT04562727

Microwave Ablation Combined With Chemotherapy for Colorectal Liver Metastases： a Multicenter Cohort Study

AI 简述这是一项观察性研究，评估微波消融联合化疗用于结直肠癌肝转移。

?

适用疾病: Colorectal Carcinoma；Chemotherapy；Liver Metastases
干预: Chemotherapy
地点: 未列出
申办方: Ping Liang

即将招募 Phase 2 药物

ClinicalTrials.gov NCT04845490

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

AI 简述这是一项II期试验，比较丝裂霉素与洛铂用于结直肠癌根治术后腹腔热灌注化疗。

?

适用疾病: Colorectal Cancer；Chemotherapy Effect；Surgery
干预: Mitomycin，Lobaplatin
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05720559

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

AI 简述这是一项II期试验，研究奥沙利铂、S1、西妥昔单抗、甲硝唑用于预防结直肠癌肝转移。

?

适用疾病: Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
干预: Oxaliplatin，S1，Cetuximab，Metronidazole
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05841134

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

AI 简述这是一项II期试验，研究Tislelizumab联合化疗围手术期治疗MSI-H/dMMR II/III期结直肠癌。

?

适用疾病: MSI-H Colorectal Cancer；Tislelizumab；Oxaliplatin
干预: Tislelizumab
地点: 未列出
申办方: The First Affiliated Hospital of Zhengzhou University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06014944

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

AI 简述这是一项II期试验，研究短程放疗联合呋喹替尼和PD-1单抗用于直肠癌。

?

适用疾病: Rectal Cancer
干预: Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
地点: 未列出
申办方: Changhai Hospital

即将招募 Phase 1, Phase 2 联合产品

ClinicalTrials.gov NCT06047015

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

AI 简述这是一项1/2期试验，研究不可逆电穿孔联合免疫治疗用于IV期结直肠癌肝转移。

?

适用疾病: Liver Metastasis Colon Cancer
干预: IRE plus checkpoint inhibitor，IRE plus Checkpoint Inhibitor plus CpG-ODN
地点: 未列出
申办方: University of Saskatchewan

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06218888

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

AI 简述这是一项II期试验，研究Tislelizumab联合Fruquintinib和Chidamide用于不可切除或晚期MSS/pMMR结直肠癌肝转移。

?

适用疾病: Colo-rectal Cancer
干预: Tislelizumab，Fruquintinib，Chidamide
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06484153

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

AI 简述这是一项I/II期试验，研究呋喹替尼联合吡非尼酮和PD-1抑制剂用于晚期pMMR/MSS结直肠癌。

?

适用疾病: To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma；To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer；Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
干预: Pirfenidone，Fruquintinib，Pembrolizumab
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06746545

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

AI 简述这是一项II期试验，研究Fruquintinib联合S-1用于转移性结直肠癌。

?

适用疾病: Colorectal Cancer
干预: Fruquintinib+S-1
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 EARLY / Phase 1 联合产品

ClinicalTrials.gov NCT06931873

Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer

AI 简述这是一项早期I期试验，研究新辅助放化疗联合QL1706用于低位直肠癌。

?

适用疾病: Rectal Cancer
干预: SCRT+Capoex+QL706，LCRT+Capoex+QL706
地点: 未列出
申办方: Changhai Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07007767

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

AI 简述这是一项II期试验，探索信迪利单抗联合贝伐珠单抗和地西他滨用于晚期pMMR/MSS结直肠癌。

?

适用疾病: Colorectal Cancer Metastatic
干预: sintilimab，Bevacizumab Biosimilar，Decitabine
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07051785

Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer

AI 简述这是一项II期试验，比较Fruquintinib联合脂质体伊立替康和卡培他滨与贝伐珠单抗联合方案用于转移性结直肠癌二线治疗。

?

适用疾病: Colorectal Cancer (CRC)
干预: Fruquintinib+Irinotecan Liposome+Capecitabine，Bevacizumab+Irinotecan Liposome+Capecitabine
地点: 未列出
申办方: Liu Huang

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07094893

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

AI 简述这是一项4期试验，在西妥昔单抗用于右侧晚期野生型RAS且AREG/EREG高表达结直肠癌。

?

适用疾病: Colorectal Cancer
干预: Cetuximab (EGFR inhibitor)，Bevacizumab，Irinotecan (CPT-11)，Oxaliplatin
地点: 未列出
申办方: Gruppo Oncologico del Nord-Ovest

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07224022

Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer

AI 简述这是一项II期试验，研究Cemiplimab联合Fianlimab用于可切除的非转移性结肠癌。

?

适用疾病: Colon Cancer
干预: Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
地点: 未列出
申办方: John Strickler, M.D.

即将招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT07243938

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

AI 简述这是一项2期篮式试验，研究Zanidatamab联合Tislelizumab用于HER2阳性胃肠道肿瘤。

?

适用疾病: Locally Advanced Rectal Cancer (LARC)；Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma；Metastatic Colorectal Cancer (mCRC)
干预: short-course radiotherapy，Zanidatamab，Tisleizumab(BGB-A317)，Capecitabine
地点: 未列出
申办方: Tao Zhang

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07260058

Immune Cell Therapy for Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究自体免疫细胞联合标准化疗用于晚期实体瘤。

?

适用疾病: Lung Cancer (Locally Advanced or Metastatic)；Liver Cancer (Locally Advanced or Metastatic)；Colorectal Cancer (Locally Advanced or Metastatic)
干预: Autologous immune Cells，Standard chemotherapy
地点: 未列出
申办方: Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07268677

A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.

AI 简述这是一项II期试验，研究吡非尼酮联合信迪利单抗及标准新辅助化疗用于结直肠癌腹膜转移。

?

适用疾病: Colorectal Cancer
干预: pirfenidone plus sintilimab combined with standard neoadjuvant chemotherapy
地点: 未列出
申办方: Guoxiang Cai

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07337551

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

AI 简述这是一项II期试验，研究Gossypol acetate联合Bevacizumab和FOLFIRI用于转移性结直肠癌。

?

适用疾病: Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
干预: Gossypol acetate Combined with Bevacizumab and FOLFIRI
地点: 未列出
申办方: Guiying Wang

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07502014

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

AI 简述这是一项II期试验，研究Iparomlimab和Tuvonralimab联合呋喹替尼和放疗用于三线及以上转移性结直肠癌。

?

适用疾病: Metastatic Colorectal Cancer (CRC)；mCRC
干预: Iparomlimab and Tuvonralimab (QL1706)，Fruquintinib，Heterogeneous Radiotherapy
地点: 未列出
申办方: Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07509424

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

AI 简述这是一项II期试验，研究短程放疗联合disitamab vedotin、sintilimab和capecitabine用于局部晚期HER2阳性直肠癌。

?

适用疾病: Rectal Cancer
干预: disitamab vedotin, sintilimab, capecitabine
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07510932

Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)

AI 简述这是一项II期试验，研究Fruquintinib用于标准治疗失败的转移性结直肠癌。

?

适用疾病: Colon Cancer
干预: Fruquintinib
地点: 未列出
申办方: Korea University Anam Hospital

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07551778

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究异体NK细胞联合标准维持治疗用于晚期非小细胞肺癌、结直肠癌等实体瘤。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；Colorectal Cancer；Advanced Solid Tumors
干预: NK Cells，NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy，NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
地点: 未列出
申办方: BOE Technology Group Co., Ltd.

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07591597

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

AI 简述这是一项Ib/II期试验，研究S-531011联合Fruquintinib或联合Fruquintinib和Pembrolizumab用于MSS/pMMR结直肠癌。

?

适用疾病: Metastatic Colorectal Neoplasms；Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
干预: S-531011，Fruquintinib，Pembrolizumab
地点: 未列出
申办方: National Cancer Center Hospital East

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07631871

An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

AI 简述这是一项II期试验，研究Zanidatamab用于HER2阳性晚期实体瘤。

?

适用疾病: Neoplasms；Solid Tumors；HER2 Positive Solid Tumor
干预: Zanidatamab
地点: 未列出
申办方: Haihua Yuan

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07631884

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

AI 简述这是一项II期试验，研究Trastuzumab Rezetecan用于HER2表达晚期实体瘤。

?

适用疾病: Solid Tumors；Neoplasms (Cancer / Tumors)；Advanced Malignant Solid Neoplasm
干预: Trastuzumab Rezetecan
地点: 未列出
申办方: Haihua Yuan

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07656038

Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer

AI 简述这是一项I期试验，研究Nelmastobart联合TAS-102和Bevacizumab用于复发/转移性结直肠癌。

?

适用疾病: Colonrectal Cancer (CRC)
干预: Nelmastobart in combination with TAS-102 and Bevacizumab
地点: 未列出
申办方: STCube, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07677579

NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer

AI 简述这是一项2期试验，研究Retifanlimab和Zanzalintinib用于转移性结肠癌。

?

适用疾病: Colon Cancer Metastatic
干预: Retifanlimab，Zanzalintinib
地点: 未列出
申办方: Northwell Health

术语	中文意思	对找临床试验有什么用
结直肠癌 / Colorectal cancer	包括结肠癌和直肠癌。不同部位、分期和分子特征会影响试验条件。	可以先用 colorectal cancer broad search，再用 colon 或 rectal 细化。
MSI-H / dMMR	提示错配修复功能异常或微卫星高度不稳定。	可以找免疫治疗、checkpoint inhibitor 等相关试验。
MSS / pMMR	微卫星稳定或错配修复功能完整，是转移性结直肠癌中常见情况。	很多试验会区分 MSI-H 和 MSS，MSS 患者常需要单独搜索。
KRAS / NRAS	RAS 基因状态会影响部分靶向治疗选择和试验入组。	试验可能要求 RAS wild-type，或针对特定 RAS 突变。
BRAF V600E	BRAF 的一种具体突变类型。	可以找 BRAF/MEK/EGFR 联合靶向相关试验。
HER2-positive	部分结直肠癌可能存在 HER2 扩增或高表达。	可以找 HER2 靶向药或 ADC 相关试验。
转移性结直肠癌 / metastatic colorectal cancer	癌症已经扩散到远处器官，比如肝、肺、腹膜等。	很多试验会限定 metastatic 或 unresectable 患者。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

结直肠癌

当前同步到的治疗类试验